Pathogenic Mechanisms Underlying Immune Dysregulation Associated To Hypomorphic RAG2 Mutation: Role Of Microbiota At Mucosal Interfaces by Rigoni, Rosita
Open Research Online
The Open University’s repository of research publications
and other research outputs
Pathogenic Mechanisms Underlying Immune
Dysregulation Associated To Hypomorphic RAG2
Mutation: Role Of Microbiota At Mucosal Interfaces
Thesis
How to cite:
Rigoni, Rosita (2018). Pathogenic Mechanisms Underlying Immune Dysregulation Associated To Hypomorphic
RAG2 Mutation: Role Of Microbiota At Mucosal Interfaces. PhD thesis. The Open University.
For guidance on citations see FAQs.
c© 2018 The Author
Version: Version of Record
Copyright and Moral Rights for the articles on this site are retained by the individual authors and/or other copyright
owners. For more information on Open Research Online’s data policy on reuse of materials please consult the policies
page.
oro.open.ac.uk
1 
	
Rosita Rigoni 
Personal identifier: C810628X 
Master Degree in Biotechnology 
 
PATHOGENIC MECHANISMS UNDERLYING 
IMMUNE DYSREGULATION ASSOCIATED TO 
HYPOMORPHIC RAG2 MUTATION: ROLE OF 
MICROBIOTA AT MUCOSAL INTERFACES 
 
A thesis submitted for the degree of 
DOCTOR OF PHILOSOPHY 
The Open University  
School of Life, Health and Chemical Sciences 
 
Affiliated Research Center: IRCCS Istituto Clinico 
Humanitas 
 
 
Date of submission: February 2018 
2 
	
 
LIST OF CONTENTS 
 
 
LIST OF CONTENTS .................................................................................................... 2 
1. ABSTRACT ................................................................................................................. 6 
2. DECLARATION ........................................................................................................ 7 
3. PREFACE .................................................................................................................... 8 
4. LIST OF FIGURES AND TABLES .......................................................................... 9 
5. ABBREVIATIONS ................................................................................................... 11 
6. INTRODUCTION .................................................................................................... 17 
6.1 Primary immunodeficiency disorders ................................................................... 17 
6.1.1 Innate Immunodeficiency ............................................................................... 17 
6.1.2 Adaptive Immunodeficiency .......................................................................... 18 
6.1.2.1 Antibody Deficiency ................................................................................ 18 
6.1.2.2 T Cell-Deficiency .................................................................................... 19 
6.1.2.3 PIDs associated to V(D)J recombination process .................................... 20 
6.1.2.3.1 V(D)J Recombination Process .......................................................... 20 
6.1.2.4 Defects in V(D)J components other than RAG ....................................... 22 
6.2 The Omenn Syndrome .......................................................................................... 24 
6.2.1 Molecular bases .............................................................................................. 24 
6.2.2 Clinical presentation ....................................................................................... 25 
6.2.3 Immunological Features ................................................................................. 26 
6.2.4 Treatment and management ........................................................................... 26 
6.2.5 Diagnosis ........................................................................................................ 28 
6.3 The mouse models of Omenn Syndrome .............................................................. 30 
6.3.1 The Rag1(R972Q) mice ................................................................................. 30 
3 
	
6.3.2 The Rag1 (S723C) mice ................................................................................. 30 
6.3.3 The Rag2(R229Q) mice ................................................................................. 31 
6.4 The gastrointestinal (GI) tract ............................................................................... 33 
6.4.1 Intestinal manifestations in PIDs .................................................................... 33 
6.4.2 Anatomy and physiology of GI tract .............................................................. 34 
6.4.3 Intestinal microbiota ....................................................................................... 35 
6.4.4 Intestinal innate immune defenses: physical and chemical barrier ................ 36 
6.4.4.1 Intestinal epithelial cell functions ............................................................ 38 
6.4.5 Intestinal immune cells ................................................................................... 38 
6.4.5.1 Dendritic cells .......................................................................................... 38 
6.4.5.1.1 DCs and gut-homing imprinting on T cells ....................................... 39 
6.4.5.2 Intraepithelial lymphocytes ...................................................................... 40 
6.4.5.3 Lamina propria T cells ............................................................................. 41 
6.4.5.3.1 T-helper1 cells ................................................................................... 41 
6.4.5.3.2 T-helper 17 cells ................................................................................ 42 
6.4.5.3.3 T Regulatory cells ............................................................................. 42 
6.4.5.4 IgA-producing B cells and plasma cells .................................................. 44 
6.4.6 Role of intestinal microbiota in IBD .............................................................. 48 
6.4.7 Microbiota and extra-intestinal diseases ........................................................ 50 
6.5 The Skin compartment .......................................................................................... 52 
6.5.1 Skin manifestations in PIDs ........................................................................... 52 
6.5.2 Skin anatomy and physiology ........................................................................ 54 
6.5.3 Skin microbiota .............................................................................................. 55 
6.5.4 Innate immune barrier in the skin ................................................................... 56 
6.5.4.1 Keratinocytes ........................................................................................... 57 
6.5.4.2 Antimicrobial peptides ............................................................................. 58 
6.5.4.3 Dendritic cells .......................................................................................... 59 
6.5.4.3.1 DCs and skin homing imprinting on T cells ..................................... 60 
6.5.5 Skin T cells ..................................................................................................... 60 
6.5.5.1 αβ T cells .................................................................................................. 60 
6.5.5.2 γδ T cells .................................................................................................. 61 
6.5.6 Association of the microbiota with inflammatory skin disorders .................. 63 
4 
	
7. AIM OF THE STUDY .............................................................................................. 65 
8. MATERIALS AND METHODS ............................................................................. 68 
8.1 Mice used in the study ........................................................................................... 68 
8.2 Human Samples .................................................................................................... 68 
8.2 Adoptive transfer experiments .............................................................................. 68 
8.3 Antibiotic treatment and faecal transplantation .................................................... 69 
8.4 IgA-coated bacteria ............................................................................................... 70 
8.5 ELISA assay .......................................................................................................... 70 
8.6 LPS measurement .................................................................................................. 70 
8.7 Quantification of adherent bacteria to mucosal and cutaneous epithelium ........... 71 
8.8 LP and skin preparation ........................................................................................ 71 
8.9 Lymph flow assessment using Evans blue dye ..................................................... 71 
8.10 OT-I and OT-2 adoptive transfer ........................................................................ 72 
8.11 DSS chronic treatment ........................................................................................ 72 
8.12 Co-culture DC-T cells ......................................................................................... 72 
8.13 Topical and systemic LPS ................................................................................... 72 
8.14 OVA-intradermal injection ................................................................................. 73 
8.15 Flow cytometry ................................................................................................... 73 
8.16 Quantitative real time RT-PCR ........................................................................... 74 
8.17 Histology and immunohistochemistry ................................................................ 74 
8.18 Histological score ................................................................................................ 75 
8.19 Morphometric analysis ........................................................................................ 75 
8.20 Microbiota analysis ............................................................................................. 75 
8.2.1 Cutaneous microbiota analysis ........................................................................... 76 
8.22 Statistical analysis ............................................................................................... 76 
9. RESULTS .................................................................................................................. 79 
9.1 Study of the intestinal pathology in Rag2R229Q mice ............................................. 79 
9.1.1 Intestinal inflammation affects Rag2R229Q mice ............................................. 79 
9.1.2 Rag2R229Q CD4+ T cells have enhanced gut tropism and cause colitis ........... 82 
9.1.3 Treg impairment contributes to intestinal inflammation in Rag2R229Q mice .. 84 
9.1.4 B cells are required to maintain intestinal homeostasis and avoid bacterial 
translocation in Rag2R229Q mice ............................................................................... 88 
5 
	
9.1.5 Rag2R229Q mice show altered microbial composition ..................................... 90 
9.1.6 Long-term antibiotic treatment dampens intestinal inflammation in 
Rag2R229Q mice ........................................................................................................ 92 
9.1.7 Absence of TLR microbial recognition do not reduce the intestinal 
inflammation in Rag2R229Q mice .............................................................................. 94 
9.2 Study of the skin pathology in Rag2R229Q mice ................................................... 100 
9.2.1 Rag2R229Q mice exhibit severe skin inflammation ........................................ 100 
9.2.2 Coexistence of skin and gut homing properties distinguishes the CD4+ T 
cells in Rag2R229Q mice .......................................................................................... 102 
9.2.3 Increased cutaneous DC trafficking characterized the Rag2R229Q mice ....... 105 
9.2.4 Increased vascularity characterizes the skin of Rag2R229Q mice ................... 107 
9.2.5 Epidermal barrier dysfunction characterizes the cutaneous compartment of 
Rag2R229Q mice ...................................................................................................... 108 
9.2.6 Selective shift in Rag2R229Q skin microbiota ................................................ 110 
9.2.7 Chronic activation of epithelial cells sustains skin inflammation in 
Rag2R229Q mice ...................................................................................................... 113 
9.2.8 LPS-induced inflammation is profoundly enhanced in Rag2R229Q mice ...... 116 
9.2.9 Chronic DSS treatment increases T-cell mediated skin inflammation in 
Rag2R229Q mice ...................................................................................................... 120 
10.	DISCUSSION ........................................................................................................ 123	
10.1 Study of the intestinal pathology in Rag2R229Q mice ......................................... 123	
10.2 Study of the skin pathology in Rag2R229Q mice ................................................. 128	
10.3 Conclusive remarks and future directions ......................................................... 134	
11.	BIBLIOGRAPHY ................................................................................................. 136	
 
 
 
 
6 
	
1. ABSTRACT 
 
Hypomorphic mutations in the RAG genes cause a profound immunodeficiency 
associated with multisystem autoimmune–like manifestations, mediated by 
oligoclonal self-reactive T and B cells, named Omenn Syndrome (OS). The clinical 
and immunological spectrum of OS presentation is extremely broad. Commonly, 
patients present symptoms very similar to graft-versus-host disease (GVHD) as 
inflammatory reactions particularly involve the environmental interfaces such as the 
skin and gut, leading to distinctive early onset erythroderma and protracted diarrhea. 
However, the complete comprehension of the molecular and cellular mechanisms 
underlying such autoimmune-like manifestations in OS is still puzzling. Furthermore, 
the role played by environmental triggers in the disease pathogenesis remains largely 
unknown. In this thesis, we demonstrated that in hypomorphic Rag2R229Q\R229Q mice, 
the OS murine counterpart, mucosal B cell deficiency alters the composition of the 
gut microbiota and causes bacterial translocation across the intestinal epithelium. 
Furthermore, loss of T cell tolerance to the commensal microbiota leads to gut 
inflammation sustained by Th1 and Th17 cells. Interestingly, we provided evidence 
that these gut-derived inflammatory cells disseminate in the periphery, infiltrating 
target organs. Decreasing gut bacterial load in Rag2R229Q\R229Q mice with long-term 
dosing of antibiotics reverses most of these abnormalities and normalizes serum 
hyper-IgE, a hallmark of the disease. Similar mechanisms are involved in the 
development of skin degeneration in mutant mice. Indeed, we found that 
compromised skin barrier integrity results in altered microbial load and composition, 
and dysregulated production of T cell recruiting chemokines by stimulated epithelial 
cells. Importantly, we found that the chronic intestinal inflammation synergistically 
supports the activation of skin epithelial cells and the recruitment of gut-derived 
pathogenic T cells at the cutaneous barrier. Overall, this work provided first time 
evidence that commensals and/or commensal-derived signals might play a substantial 
role in shaping immune response and autoimmunity at barrier sites and beyond in 
RAG-associated immune deficiency. 
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CD40L  CD40 ligand 
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CGD   Chronic granulomatous disease 
CHD7   Chromodomain helicase DNA binding protein 7  
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CID   Combined immunodeficiency  
CK5    Keratin 5  
CLA   Cutaneous lymphocyte associated antigen 
CMD   Corticomedullary demarcation 
CNS   Central nervous system 
CSR   Class switch recombination   
CT   Cholera toxin 
CVID   Common variable immunodeficiency 
CXCL   CX-chemokine-ligand  
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DETCs  Dendritic epidermal T cells 
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HSV   Herpes simplex virus  
IBD   Inflammatory bowel disease 
ICOS   Inducible T cell costimulator 
IECs   Intestinal epithelial cells  
IELs   Intraepithelial lymphocytes 
IFN   Interferon 
IgA   Immunoglobulin A 
IgAD   IgA deficiency     
IL   Interleukin 
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iNKT   Invariant natural killer T cells  
iNOS   Inducible nitric oxide synthase  
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PID   Primary immunodeficiency 
pIgR   Polymeric immunoglobulin receptor 
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PPs   Peyer’s patches  
PRRs   Pattern recognition receptors  
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RA   Rheumatoid arthritis 
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Th   T helper 
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TLR   Toll-Like Receptor 
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Treg   T regulatory   
TRM   Tissue resident memory T cells 
TSLP   Thymic stromal lymphopoietin 
UC   Ulcerative colitis   
UEA-1  Ulex europaeus agglutinin-1 
V(D)J    Variable (V), diversity (D) and joining (J)  
VEGF-A  Vascular endothelial growth factor A 
WAS   Whiskott-Aldrich syndrome   
WES   Whole exome sequencing  
WSG   Whole genome sequencing 
XLA   X-linked agammaglobulinaemia 
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6. INTRODUCTION 
	
6.1 Primary immunodeficiency disorders  
Primary immunodeficiency disorders (PIDs) refer to a heterogeneous group of disorders 
characterized by a poor or absent function of one or more components of the immune 
system. Over 130 different disorders have been identified to date, and new disorders are 
continually being discovered [1]. Most PIDs are associated to inherited defects in the 
immune system development and function, but some acquired forms are also reported 
[2]. Moreover, PIDs are different from secondary immunodeficiency that may result 
from other causes, such as viral and bacterial infections, malnutrition and treatment with 
drugs that induce immunosuppression. PIDs are rare and, particularly, the estimate 
prevalence in the United States is about 1 in 10,000 live births. They are broadly 
classified according to the components of the immune system that are affected: innate or 
adaptive immunity. Defects of innate immune compartment include disorders of 
phagocytes, Toll-like receptor (TLR)-mediated signalling, and complement. Defects of 
the adaptive immune responses include antibody deficiency syndromes and combined 
immunodeficiencies (CIDs).  
6.1.1 Innate Immunodeficiency  
Innate immunodeficiencies include a group of disorders characterized by defects in the 
development and function of innate immune components. Chronic granulomatous 
disease (CGD) is a common phagocyte disease caused by defects in the reduced 
nicotinamide adenine dinucleotide phosphate (NADPH) oxidase complex, resulting in 
an inability to produce the superoxide anion necessary for bacteria and fungi killing. 
Patients with CGD are at high risk of severe infections (skin, liver and perirectal 
abscesses, pneumonia, and lymphadenitis) [3]. In humans, mutations in genes involved 
in TLR-mediated signalling result in a selective susceptibility to pathogens. Moreover, a 
large variety of inherited defects of complement components have been described. In 
particular, deficiency of early components of the classical pathway (C1q, C1r, C1s, C4, 
C2 and C3) causes autoimmune manifestations resembling systemic lupus 
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erythematosus. Defects of the late complement components (C5-C9) are associated with 
severe neisserial infections [4].     
6.1.2 Adaptive Immunodeficiency 
Deficiencies in antibody production and function represent the hallmark of PIDs that 
involve B cells. B-cell defects show increased susceptibility to bacterial infections, 
involving particularly the respiratory tract. Abscesses in the skin and in other organs, 
meningitis and urinary tract defects are also described in patients [2].  
CIDs include a heterogeneous group of disorders with impaired development, function, 
or both of T cells, associated with a defective antibody response [5]. In most severe 
forms of CIDs, also known as severe combined immunodeficiency (SCID), there is a 
complete lack of T lymphocytes. SCID defects are classified based on the 
immunological features and are divided in: (1) SCID with absence of T lymphocytes (T-
B+SCID) or (2) SCID with absence of both T and B lymphocytes (T-B- SCID). Patients 
with SCID present similar features, including early-onset severe respiratory tract 
infections, chronic diarrhoea, and failure to thrive. 
6.1.2.1 Antibody Deficiency 
Antibody deficiencies might depend on a variety of defects interfering with B cell 
development and functions [6]. Several forms of agammaglobulinaemia are 
characterized by a B cell defect and intact T cell function. Among all the forms, X-
linked agammaglobulinaemia (XLA) provides the prototypical clinical description. It 
results from a mutation in the gene encoding Bruton’s tyrosine kinase (BTK), which has 
a crucial role in B cell development [7]. Indeed, patients present a low number of 
circulating B cells and extremely low levels of all serum immunoglobulin. The 
Common Variable Immunodeficiency (CVID) is characterized by a defect in antibody 
production. In particular, the level of circulating B cells is reduced or normal, and these 
cells respond and proliferate normally to antigens. However, they fail to terminally 
differentiate to plasma cells, which secrete antibodies [8]. The classical mutated genes 
include the inducible T cell co-stimulator (ICOS) and SH2 domain containing protein 
1A (SH2D1A). Recently, three additional genes have been associated to the disease: 
CD19, B cell-activating factor receptor (BAFFR) and transmembrane activator and 
calcium-modulating cyclophilin-ligand interactor (TACI). Patients with CVID present 
19 
	
increased risk of developing infections, autoimmune diseases, gastrointestinal and 
pulmonary conditions, and malignancies. Selective IgA Deficiency (IgAD) represents 
the most common PID [9]. The molecular defect, leading to the absence of IgA class 
switching, is unknown in most cases. Recurrent pyogenic sinopulmonary infections are 
associated with IgAD. In addition, hyper-IgM syndromes (HIGMs) represent a group of 
molecular defects characterized by impaired immunoglobulin class switch 
recombination (CSR) and somatic hypermutation (SHM) or by impaired SHM alone. 
Patients with these syndromes have recurrent bacterial infections and, often, lymphoid 
hyperplasia. Moreover, they have normal number of peripheral B cells but few memory 
B cells, resulting in normal or increased levels of serum IgM and low or absent levels of 
serum IgG, IgA and IgE. Several genetic defects have been identified associated to the 
disease, including defects in CD40 ligand (CD40L), activation-induced cytidine 
deaminase (AID) and CD40.  
6.1.2.2 T Cell-Deficiency 
The pathogenesis of SCID affects several steps in T cell development [5]. Adenosine 
deaminase (ADA) deficiency showed impaired survival of lymphocyte precursors. In 
particular, ADA is an enzyme of the purine salvage pathway that induces the conversion 
of adenosine (and deoxyadenosine) to inosine. In the absence of ADA, the apoptosis of 
lymphoid precursors in the bone marrow and in the thymus is caused by high 
intracellular levels of toxic phosphorylated metabolites of adenosine and 
deoxyadenosine [10]. ADA deficiency accounts for 10%-15% of all forms of SCID. 
Clinical manifestations in ADA patients extend beyond the immune system, ranging 
from deafness, behavioural problems, costochondral abnormalities and liver toxicity. 
Defects of cytokine-mediated signalling are responsible for the majority of SCID in 
humans. SCID-X1 (X-linked SCID) is caused by mutations of the interleukin (IL)-2 
receptor γ gene (IL2Rγ), which encodes for the γ chain (γc) shared by cytokine 
receptors for IL-2, IL-4, IL-7, IL-9, IL-15, IL-21. Patients with SCID-X1 lack both T 
and natural killer (NK) cells, whereas they have normal number of circulating B 
lymphocytes [11]. The γc is physically and functionally coupled to the intracellular 
tyrosine kinase Janus kinase (JAK) 3, which delivers γc-mediated intracellular 
pathways. Indeed, defects of JAK3 present an immunologic phenotype indistinguishable 
from that of SCID-X1 [12]. Moreover, mutations in the IL7R (IL-7 receptor) gene, 
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which encodes for the α chain of the IL-7R, abrogate T cell development but NK and B 
cell development remains normal [13]. Defective expression of MHC class II (MHCII) 
molecules is also reported in patients. The disease is characterized by CD4+ T cell 
lymphopenia with a severe clinical course [14]. Moreover, hypomorphic mutations in 
RAG genes, which allow residual T cell development, are typically associated with 
SCID [2]. Other T cell-immunodeficiencies caused by thymic defects have been 
described, including DiGeorge syndrome (DGS) and Forkhead box N1 (FOXN1) 
deficiency [15]. 
6.1.2.3 PIDs associated to V(D)J recombination process 
A variety of genetic mutations associated to PIDs result in defects of the protein 
machinery required for the variable (V), diversity (D) and joining (J) recombination 
process, critical for producing the diverse repertoire of the developing T- and B- cells. 
Defects in V(D)J recombination process account for about 30% of human SCID cases 
and lead to an early arrest of both T and B cell development. This process is carried out 
by different molecules, including the recombination activating genes, RAG1 and RAG2. 
Approximately in 70% of SCID patients, mutations are found in the RAG1 and RAG2 
genes [16]. Hypomorphic mutations in RAG genes that support partial recombination 
activity were identified in infants with Omenn Syndrome (OS), a disease characterized 
by immune dysregulation and the presence of residual oligoclonal, activated T cells 
infiltrating multiple organs [17-19].  
6.1.2.3.1 V(D)J Recombination Process 
To obtain the necessary level of diversity, B and T cell receptors are created by 
recombination of the pre-existing encoding gene segments. These V(D)J gene segments 
are found as multiple copies that lie upstream of a constant (C) region; these segments 
are rearranged to yield a contiguous V(D)J region and assemble a single functional 
receptor in a process defined V(D)J recombination process. This process takes place in 
the bone marrow or in the thymus and is crucial for the production of mature B and T 
cells, respectively. Schematically, the V(D)J recombination process can be divided into 
three steps (Figure 1). In the first phase, two recombination activating proteins RAG1 
and RAG2 recognize and bind to recombination signal sequences (RSSs) that flank all 
V and J segments and introduce a double strand-break at the border of RSS. On the 
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chromosome, coding ends are left as hairpin-sealed structures, whereas signal ends, 
which are excised from the chromosome, are blunt and 5’ phosphorylated. The second 
steps are taken care by the DNA-repair machinery of the non-homologous end-joining 
(NHEJ) apparatus. The double strand-break is first recognized by the DNA-dependent 
protein kinase (DNA-PK) complex formed by the Ku70-Ku80 heterodimer, which binds 
to DNA ends, and the DNA-PK catalytic subunit (DNA-PKcs). Before re-ligation, the 
hairpins at the coding ends are first opened, presumably by the Artemis-DNA-PKcs 
complex. During the third step of the V(D)J recombination, the lymphoid-specific 
terminal deoxynucleotidyl transferase (TDT) enzyme further increases joining diversity 
by adding non-templated nucleotides to processed coding ends. Finally, the 
XRCCA/DNA ligase IV/Cernunnos complex catalyses the ligation step. 
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Figure 1: The V(D)J recombination process. It can be divided into three steps: (A) The 
RAG1/2 genes recognize the RSS and introduce a double strand break. (B) Artemis, 
which is recruited and phosphorylated by Ku/DNA-PK complex, opens the hairpins 
through its endonuclease activity. (C) The XRCC4/DNA ligase IV/Cernunnos complex 
seals coding and signal joins (Adapted from [20]). 
6.1.2.4 Defects in V(D)J components other than RAG 
Mutations in other V(D)J recombination components have been reported in patients, 
including Artemis, DNA ligase IV and DNA PKcs genes. Affected patients show 
increased sensitivity to ionizing radiation. The Artemis protein, in complex with DNA-
PKcs, performs the crucial NHEJ function of opening the DNA hairpins created by the 
RAG complex, and then acts to nucleotycally trim the ends to variable extents. 
Mutations in the Artemis gene represent the most common cause of radiosensitive SCID 
[21]. DNA-ligase IV is an enzyme in the final DNA re-joining step of NHEJ. Studies 
showed the embryonic lethality of mice that are deficient in DNA ligase IV and 
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XRCC4, underlying the crucial role of these factors for viability [22]. DNA-PKcs is the 
partner of Artemis in DNA hairpin-opening complex. Van der Burg et al. described the 
first human case of DNA-PKcs, showing that residual DNA-PKcs activity is 
indispensable in humans [23].  
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6.2 The Omenn Syndrome  
Omenn syndrome is an autosomal recessive disease associated to early onset 
erythroderma, lymphadenopathy, eosinophilia and severe immunodeficiency. Affected 
patients display a unique combination of clinical and laboratory findings typical of 
severe immunodeficiency and autoimmune conditions [19]. The association between 
immunodeficiency and autoimmunity may represent a paradox in OS pathogenesis. The 
genetic defects that affect T and B development compromise not just the ability to 
generate a diversified repertoire capable to recognise foreign antigens, but also impinge 
on central and peripheral tolerance, thus favouring autoimmune manifestations [24].    
6.2.1 Molecular bases 
The vast majority of OS cases relies on hypomorphic mutations in RAG1 and RAG2 
genes, which impair but not abolish the V(D)J recombination process. The biochemical 
studies of RAG1 and RAG2 mutants revealed the fundamental role of the different 
RAG gene domains, essential for the catalytic activities of the proteins [25]. Frequently, 
RAG1 mutations map to domains involved in the recognition of DNA binding and in 
particular, regions that recognize and bind the RSS flanking the T and B cell receptor 
gene sequences [26]. Other mutations map to domains involved in the recruitment of the 
RAG2 protein, leading to a stable complex for DNA bending and cleavage. In addition, 
the majority of the mutations found in OS cause changes in amino acids, impairing the 
activity of RAG proteins. Deletions at the N-terminus of RAG1 have been also 
described. OS was also identified in patients with mutations in DCLRE1C gene, 
encoding for Artemis, which mediates hairpin coding end opening during the V(D)J 
recombination process [27]. In addition, mutations in RMRP gene (RNA component of 
mitochondrial RNA-processing endoribonuclease) have been discovered as a possible 
cause of OS [28]. Furthermore, homozygosity for a missense (C118Y) mutation in the 
IL7R gene, encoding the α chain of the IL7R and essential for T cell development, has 
been found as a rare cause of OS, with a normal number of circulating B cells [29]. 
Recently, patients with OS associated to ADA deficiency have been described [30]. 
Interestingly, patients with DiGeorge syndrome [31] or leaky SCID with hypomorphic 
mutations in the IL-2R γ [32], IL-7R α [29], chromodomain helicase DNA binding 
protein 7 (CHD7) [33] or DNA ligase 4 [34] presented with OS. Based on these 
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observations, OS is not characterized by a specific genetic defect, but it could be 
defined as a combination of aberrant inflammatory conditions and multiple genetic 
defects that abrogate, but not abolish, T-cell development in the thymus.  
6.2.2 Clinical presentation 
A peculiar clinical spectrum characterizes OS, which was first described in 1965 (Table 
1) [35]. OS has been defined as a SCID with erythroderma, hepatosplenomegaly, failure 
to thrive, susceptibility to infections, chronic diarrhoea, and a fatal outcome unless 
treated with hematopoietic stem cell transplantation (HSCT). Several cases of 
pneumonitis were also reported in OS, generally caused by Pneumocystis jiroveci or 
virus such as cytomegalovirus or parainfluenza [19]. Besides erythroderma, other skin 
manifestations are described in OS patients: psoriasis and alopecia are common 
features, while vitiligo has been recently reported as a unique clinical sign in the 
absence of over immunological defects [36]. Rash may be present at birth or evolve 
over the first few weeks of life. Furthermore, a significant protein loss thought the skin 
and the gut is reported in OS patients, leading to generalized edema and metabolic 
disorders. Interestingly, OS disease has been also recently associated with a novel 
phenotype characterized by granuloma formation, Epstein Barr virus (EBV)-related 
lymphoma and survival into late childhood [37]. Importantly, symptoms of OS patients 
can evolve with time and may not appear simultaneously. Moreover, several patients 
present some but not all signs consistent with the disease and are commonly known as 
affected by atypical form of OS [25] 
 
 
 
 
 
 
 
Classical SCID Omenn Syndrome (OS) 
    
Present in infancy  Present in infancy  
Persistent viral respiratory +/- gastrointestinal 
infections  
Erythroderma 
Pneumocystis jiroveci pneumonitis  Alopecia 
Disseminated BCG infection  Hepatosplenomegaly  
Failure to thrive Massive lymphadenopathy 
Superficial candidiasis Inflammatory 
pneumonitis/enteritis 
Maternofetal GVHD Hyper-IgE 
Absent lymphoid tissue Eosinophilia  
Absent immunoglobulins Lymphocytosis 
Absent T cells   
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Table 1: Main features of classical SCID and Omenn Syndrome (Adapted from [38]).  
 
6.2.3 Immunological Features  
Hypomorphic mutations in RAG genes allow the development of a normal or elevated 
number of T lymphocytes with limited repertoire diversity. These T cells are highly 
activated, oligoclonally expanded and commonly present a Th2 phenotype [25]. Such T 
cells infiltrate several organs, including skin, gut, spleen and liver, resulting in profound 
tissue damage [39]. Abnormalities of thymic architecture, with a loss a cortico-
medullary demarcation and absence of Hassall bodies were reported in OS patients. In 
addition, the lack of Aire (AutoImmune REgulator) expression and of Aire-dependent 
tissue restricted antigens (TRAs) is severely reduced [40]. Moreover, T regulatory 
(Treg) impairment has been demonstrated in the thymus of patients [41]. In addition, 
reduced suppressive activity and abnormal phenotype (CCR7-CD45RA-) characterizes 
the Treg population in OS [42]. All these findings suggest an impairment of both central 
and peripheral tolerance that actively contributes to autoimmunity, typical of OS [42, 
43]. 
In contrast to T cells, circulating B cells are typically reduced or absent, but plasma 
cells (Blimp1+CD138+) can be detected in lymphoid organs and are responsible for the 
low levels of immunoglobulin, with the exception of IgE, which are often increased [44, 
45]. Remarkably, a broad range of autoantibodies has been detected in patients [46], 
indicating that B cell tolerance is also disrupted in OS. Increased levels of serum BAFF, 
found in RAG deficient patients and reflecting B cell lymphopenia and inflammation 
[44], are likely responsible for the survival of autoreactive B cells. Interestingly, 
activated T cells and ectopic distribution of Langerhans cells characterized the OS 
biopsies [47]. Finally, defects of invariant natural killer T cells (iNKT) contribute to the 
immune dysregulation in OS [48].  
6.2.4 Treatment and management 
If untreated, patients with OS have a fatal prognosis. In particular, skin inflammation 
worsens over time, leading to higher susceptibility to bacterial and fungal infections. 
The treatment with drugs including prednisone and cyclosporin A proved effective in 
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suppressing the expansion of T cell clones and organs infiltration [49]. However, in 
absence of HSCT, OS remains a fatal disease due to current infections and high 
mortality early in life. Transplantation of HSC represents instead a permanent cure [50]. 
Satisfactory results were obtained mostly with HSCT from human leucocyte antigen 
(HLA)-match family donors. In this case, pharmacological suppression of abnormal and 
activated autologous T cell clones seems to facilitate the engraftment of bone marrow 
cells. In contrast, lower survival rate was observed with HSCT from mismatched family 
donors or matched unrelated donors (MUD). However, the use of myeloablative 
regimens with busulfan and cyclophosphamide has dramatically improved the outcome 
of patients treated with HSCT from matched unrelated donors (>80% survival rate) 
[51]. 
Overall these data suggested the necessity to develop an alternative form of treatment 
for patients with RAG deficiency lacking HLA-matched donors.  
Gene therapy (GT) approach was successfully used to treat X-linked SCID [52] and 
ADA deficiency (Figure 2) [53, 54]. In both cases, a strong selective advantage for 
gene corrected-cells has been found in T cell lineage. Importantly, a study described the 
transplantation of Rag1-/- bone barrow progenitor cells transduced with a Moloney 
murine leukaemia virus carrying the human RAG1 transgene in recipient Rag1-/- mice. 
By this approach, GT-treated mice had lower-than-normal B cells [55]. This indicated 
that gene-corrected lymphoid progenitors have only a small selective advantage in the 
thymus and in the bone marrow of Rag1-/- mice. Remarkably, relatively inefficient 
expression of the gene was detected. To overcome this problem, self-inactivating 
lentiviral vectors expressing codon-optimized human RAG1 under the control of several 
regulatory elements have been developed. By this approach, partial reconstitution of T 
cell immunity and antibody response was reported although the number of B cells 
remained suboptimal [56]. By contrast, another study reported a modest reconstitution 
of both T and B cells using the same vectors. However, about 50% of GT-treated mice 
developed an OS phenotype [57].   
Promising preclinical studies were obtained with GT for RAG2 deficiency [57]. 
Significant improvement of peripheral T and B immunity, even at a relatively low copy 
number, was obtained using the vectors expressing codon-optimized human RAG2 and 
containing other modifications to reduce the risk of silencing of the RAG2 transgene. 
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These data offer hope for the development of GT approach to cure human RAG2 
deficiency. Whether this approach could be useful for treating hypomorphic mutations, 
where competition between endogenous cells and gene-transduced cells might affect the 
immune reconstitution, remains to be demonstrated.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: GT procedure. (A) HSC were collected from bone marrow of a patients. (B) 
Lentiviral-vector particles containing a functional gene were introduced in HSC. (C) To 
eradicate the patient's remaining HSCs and make room for the genetically modified 
cells, the patient underwent chemotherapy. (D) The genetically modified HSCs were 
then transplanted into the patient (Adapted from [58]). 
6.2.5 Diagnosis 
For patients with SCID without detectable enzyme deficiencies, prenatal diagnosis has 
been possible through the evaluation of lymphocyte populations and 
phytohemagglutinin (PHA)-induced lymphocyte proliferation in fetal cord blood 
samples [59]. However, cordocentesis can only be performed relatively late in 
pregnancy, between 18 and 20 weeks of gestation with abortion risk [60]. Furthermore, 
prenatal diagnosis of OS based on fetal blood samples leads to diagnostic errors due to 
the variable numbers of circulating T cells exhibiting residual in vitro proliferation in 
response to PHA. Currently, a safer and more accurate diagnosis for SCID and OS cases 
is obtained through genome sequencing of the complete coding regions of both RAG1 
B. Lentiviral vector  
particles 
A. HSCs 
C. Conditioning 
D. Genetically  
modified HSCs 
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and RAG2 from the proband and the parents [61]. From 2010 onward, next generation 
sequencing (NSG) approach is being increasingly used in the PID field [62]. 
Specifically, NSG approach is a sequencing method in which hundreds of millions of 
small DNA fragments are sequenced in parallel. Indeed, NSG can be used to sequence 
entire genome (whole genome sequencing, WSG) or targeted panel of genes, ranging 
from a small number of genes to the whole exome (WES). In the PIDs field, NSG is 
being increasingly used for the molecular diagnosis of PIDs and for the discovery of 
novel disease-causing genes [63].  
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6.3 The mouse models of Omenn Syndrome 
6.3.1 The Rag1(R972Q) mice 
Animal models that recapitulate key features of human OS have been described [64-66]. 
In particular, Khiong et al. developed the memory mutant mice (MM), so called for the 
unusual high percentage of memory phenotype T cells [64]. The MM phenotype was 
caused by a spontaneous point mutation in RAG1 gene (R972Q), which affects the 
V(D)J recombination process. The MM mice present several immunological features in 
common with OS patients, such as skin redness, hepatosplenomegaly, eosinophilia and 
increased IgE levels. In particular, spleen, lymph nodes and the thymus were 
characterized by low cellularity and abnormal morphology. Analysis of T cell 
development in the thymus revealed a partial block at the double negative 3 (DN3) 
stage (CD4- CD8- CD44- CD25+). In addition, CD4+ CD8+ double positive (DP) cells 
were decreased as number. Similar to human disease, T cells presented an oligoclonal T 
cell receptor (TCR). Moreover, MM mice developed a distinctive B cell defect. In bone 
marrow, MM mice showed a partial block in B cell development at the pro-B cell stage 
and in the spleen mainly at pre-B stage. Interestingly, mutant mice developed increased 
IgM, IgG2a and IgG2b levels. In contrast to OS features, T cell infiltration was not 
reported in tissues as well as autoimmune manifestations, such as erythroderma or 
colitis. 
6.3.2 The Rag1 (S723C) mice 
Another mouse model was generated by Giblin et al, carrying a homozygous mutation 
in the RAG1 gene (S723C) [66].  
In particular, the Rag1S723C/S723C mutation reduced the V(D)J recombination process and 
determine impaired T cell development. Activated-oligoclonal T cells, reduced 
circulating B cells but significant levels of immunoglobulin were reported in the mutant 
mice. However, only a minority of mice presents signs of autoimmunity, including 
tissue infiltration and autoantibodies.  
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6.3.3 The Rag2(R229Q) mice 
Our group developed an engineered mouse model, introducing a hypomorphic mutation 
in the RAG2 core domain-coding region by homologous recombination (Figure 3). The 
Rag2R229Q/R229Q mice recapitulate most of the clinical and immunological features of 
human pathology [44, 47, 65, 67]. 
At 3 months of age, the Rag2R229Q/R229Q mice started to develop several skin 
manifestations, including erythroderma and alopecia, wasting syndrome and colitis. 
Oligoclonal self-reactive T cells infiltrate target organs such as skin, liver, lung, kidney 
and gut. Immune dysregulation was described in the thymus of Rag2R229Q/R229Q mice. 
Indeed, marked thymic abnormalities, with lack of corticomedullary demarcation 
(CMD) and impaired maturation of thymic epithelial cells (TECs) were described. In 
addition, the mutant thymus showed severe depletion of Ulex Europeus Agglutinin-1 
(UEA-1) positive medullary thymic epithelial cells (mTECs), homogeneously 
distributed in normal thymus.  
Rag2R229Q/R229Q mice also show impairment of central and peripheral tolerance. In 
particular, reduced Aire expression was observed in the thymus, as reported in the OS 
patients. In addition, strong reduction in the frequency and the absolute number of Treg 
subset was found in hematopoietic organs. 
Furthermore, analysis of T cell development in the thymus showed an arrest at the DN3 
stage (CD44-CD25+) with absence of DP cells and reduced number of single positive 
(SP) cells. The few SP cells generated expressed TCRα/β at the cell surface and were 
exported to the periphery, where they infiltrated target organs.  
B cell differentiation was also affected in Rag2R229Q/R229Q mice, with a predominant 
block at the pre-B cell stage in the bone marrow. This resulted in a prominent reduction 
of circulating B cells and a marked hypogammaglobulinemia, despite elevated IgE 
serum levels. A larger expansion of the immunoglobulin secreting cell population could 
be detected mainly within the secondary lymphoid organs, and associated with 
upregulation of the B lymphocyte-induced maturation protein 1 (Blimp1), and 
consequent transcriptional repression of B cell lymphoma 6 protein (Bcl-6) and c-Myc. 
Furthermore, BAFF abundance was found in the serum of mutant mice. In the liver, 
complete absence of iNKT cells was observed, as described in OS patients [48]. 
Interestingly, skin infiltrate showed activated oligoclonal T cells and ectopic 
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distribution of  Langerhans cells (LCs), similarity to the human disease. The abundant 
presence of LCs in the dermis, instead of the normal distribution in the epidermis, could 
potentially contribute to the initiation of the skin manifestations in OS [47]. 
 
 
 
 
Figure 3: Scheme of the Rag2GFP targeting vector used for the generation of 
Rag2R229Q/R229Q mice. Specifically, a targeting vector was designed to replace 
endogenous Rag2 with the gene carrying the R229Q substitution and an NheI 
restriction site. GFP was fused in frame with the Rag2 neo cassette flanked by loxP 
sites (arrows) (Adapted from [65]). 
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6.4 The gastrointestinal (GI) tract  
6.4.1 Intestinal manifestations in PIDs 
Patients with PIDs can present IBD-like gastrointestinal pathology, manifesting in the 
25% of cases during the childhood. In several PIDs, intestinal manifestations due to 
immune dysregulation are the initial or the leading symptom and may manifest before 
other characteristics of PIDs. In other cases, gastrointestinal pathology is the result of an 
increased susceptibility to infections.    
Intestinal granulomas are detected in nearly 50% of CGD patients and up to 17% of 
these patients develop colitis [68]. Moreover, patients with mutation in IL-10 receptor 
and IL-10 genes can develop early onset enterocolitis [69]. Gastrointestinal disease can 
also be present in other PIDs, including Whiskott-Aldrich syndrome (WAS), 
immunodysregulation, polyendocrinopathy and enteropathy, X linked (IPEX) syndrome 
and NF-kB essential modulator defects. Intestinal disorders affect also SCID patients. 
Severe diarrhea and malabsorption early in life are found in these patients. Frequent 
cytomegalovirus, rotavirus and adenovirus infections have been reported. Moreover, 
patients with SCID who receive blood transfusions and allogenic HSCT are susceptible 
to graft-versus-host disease (GVHD), a severe condition affecting both small and large 
intestine [70]. Patients with OS developed severe IBD-like immunopathology [71]. 
CVID is also associated with intestinal inflammation, favored by the dysregulation of 
the T-cell mediated cytokine production [72]. IBD-like phenotype was also observed in 
patients with hyper-IgM and in patients with agammaglobulinemia [73].  
Genomics studies have recently provided important insights into the pathogenesis of 
PIDs and inflammatory bowel disease. In particular, genome-wide association studies 
(GWAS) revealed that known IBD risk loci are particularly enriched for genes involved 
in PIDs, including those linked to reduced levels of circulating T cells (ADA, CD40, 
TAP1, TAP2, NBS1, BLM, DNMT3B), and to T-helper cells responsible for producing 
IL-17, memory (STAT3, SP110), and regulatory T cells (STAT5B). 
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6.4.2 Anatomy and physiology of GI tract 
The gastrointestinal tract (GI) hosts the largest compartment of the immune system. It is 
continually exposed to a wide range of antigens and potential immune stimuli derived 
from the diet and the commensal bacteria. The GI tract is a large and muscular tube, 
which extends from the mouth to the anus. It consists of the esophagus, stomach and 
intestines, divided in small and large (Figure 4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Anatomy of the human GI tract. 
The small and the large intestines form a continuous tube that is lined internally by a 
single layer of columnar epithelium and extends from the stomach to the anus. The 
small intestine (SI) begins at the pylorus and ends at the ileocaecal valve, which is the 
entry point into the large intestine. Three segments compose the small intestine: the 
duodenum, the jejunum and the ileum. As to the large intestine, it begins at the caecum, 
followed by the ascending, the transverse, the descending colon and the rectum, 
terminating at the anus. Differences in size characterize the small and large intestines; 
the small intestine consists of multiple coins amounting to 6-7 meters in length; the 
colon is wider in diameter and shorter (1.5 meters). The small intestine is characterized 
Stomach 
Esophagus 
Small Intestine 
Large Intestine 
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by finger-like projections know as villi, which extend into the lumen (Figure 5). In 
contrast, villi are not present in the caecum and in the colon [74]. The main role of small 
intestine consists in the nutrient uptake from the intestinal lumen and the distribution in 
the blood circulation. On the contrary, the reabsorption of water and the elimination of 
undigested foodstuffs represent the main functions of large intestine.  Interspersed 
throughout the intestine are gut-associated lymphoid tissues (GALT), including Peyer’s 
patches (PPs) in the small intestine and isolated lymphoid follicles (ILFs) in the colon.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Anatomy of the human small intestine. The GI tract is throughout divided 
into four layers: the mucosa (epithelium, LP, muscularis mucosae), submucosa, 
muscular layer and the serosa. 
6.4.3 Intestinal microbiota 
The microbiota that colonizes the intestine contains about 1014 microorganisms. The 
number of bacteria increases going down the intestine, ranging from 105 per ml in the 
upper small intestine and up to 1012 in the large intestine (Figure 6). Approximately 
500-1000 species belong to the major phyla. The relative number of these varies among 
individuals but the Firmicutes, Bacteroidetes, Proteobacteria and Actinobacteria are the 
most prevalent taxa. Members of Archaea kingdom are also present [74].  
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Figure 6: Anatomy of the GI tract and distribution of commensal microbes along the 
length of the intestine (Adapted from [74]).  
6.4.4 Intestinal innate immune defenses: physical and chemical barrier 
In the GI tract, highly specialized defense barriers have evolved to confine the 
microbiota and to resist to invading harmful organisms. To this aim, intestinal epithelial 
cells (IECs) generate various types of barriers: physical and chemical barriers (Figure 
7). Physical barrier includes the mucus layer covering the intestinal mucosa, the 
glycocalyx on the microvilli of absorptive IECs, and the cell junctions firmly linking 
IECs. The mucus is a viscous fluid secreted by goblet cells that is enriched in mucin 
glycoproteins. The number of goblet cells in the large intestine is much higher 
compared to small intestine. In fact, the mucus is very thick in the large intestine. Two 
layers compose the mucus: the inner, firm mucus layer and the outer, loose mucus layer. 
Both mucus layers are organized by gel forming mucin-2 (MUC2), which is highly O-
glycosylated protein produced by goblet cells. The inner mucus layer is a stratified 
mucus layer anchored to the intestinal epithelia and does not allow bacteria to invade 
the epithelium. On the contrary, the outer mucus layer is inhabited by a large amount of 
intestinal bacteria. Moreover, various antimicrobial molecules, including the defensin 
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family of proteins, secreted by IECs, and the immunoglobulin A (IgA), are involved in 
the protection against bacterial invasion of the mucus inner layer. The glycocalyx, a 
meshwork of carbohydrate moieties of glycolipids and glycoproteins, protect the 
intestinal mucosa from invading bacteria. In addition, cell junctions, such as tight and 
adhesion junctions linking epithelial cells hamper the microbial invasion through the 
paracellular pathways [75]. Chemical barriers, including antimicrobial peptides (AMPs) 
and the regenerating islet-derived 3 (Reg3) family of proteins produced by IECs, have a 
crucial role in the segregation of intestinal bacteria and epithelial cells [76]. AMPs 
include the defensin family (α-, β- and θ-defensins) and the cathelicidins, both of which 
interact with the negatively charged microbial cell membrane and cause membrane 
disruption by forming pore-like structures [77]. The Reg3 family of proteins includes 
many antimicrobial proteins mainly produced by Paneth cells. In particular, Reg3γ is 
active against Gram-positive bacteria and has a critical role in the spatial separation of 
the intestinal bacteria and the epithelium of the small intestine [76].  
 
 
Figure 7: Physical and chemical barrier in the intestine. In the small intestine, 
chemical barriers, including AMPs and Reg3γ, have an important role in the 
segregation between intestinal microbiota and IECs. In the large intestine, the inner 
mucus promotes the segregation between microbiota-IECs. Tight and adhesion 
junctions limit the microbial penetration (Adapted from [75]). 
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6.4.4.1 Intestinal epithelial cell functions 
IECs express pattern recognition receptors (PRRs) and act as sensors of the microbial 
environment. Members of the TLR, NOD-like receptor (NLR) and retinoic acid 
inducible gene-1 (RIG-1)-like receptor (RLR) families provide distinct pathways for the 
recognition of microbial ligands at the intestinal level. Moreover, another function of 
IECs regards the transport of secretory immunoglobulins across the epithelial barrier. In 
particular, dimeric IgA complexes, produced by plasma cells in the lamina propria (LP), 
are bound by the polymeric immunoglobulin receptor (pIgR) on the basolateral 
membrane of IECs and are actively transcytosed into the intestinal lumen [78]. In 
addition, specialized IECs called microfold cells (M cells), mediate the sampling of 
luminal antigens and intact microorganisms for presentation to the mucosal immune 
system [79]. 
6.4.5 Intestinal immune cells  
The LP and epithelium represent the effect sites of the mucosal immune system. Indeed, 
LP contains B cells, T cells and other populations, including dendritic cells (DCs), 
macrophages, eosinophils and mast cells, whereas the epithelium contains mainly T 
cells.  
6.4.5.1 Dendritic cells 
DCs are positioned within the LP and in organized lymphoid structures and exhibit a 
dual role in tolerance and immunity in the gut. In particular, intestinal DCs transport 
bacterial antigens from the LP into the mesenteric lymph nodes (MLN) and are crucial 
for inducing oral tolerance to food antigens. Two major CD11C+ MHCII+ DCs subsets 
have been identified in the intestine: a CD103-CD11b+CXCR1+ subset that resides 
adjacent to the epithelium where they use the trans-epithelial dendrites to acquire 
luminal antigens, and a CD103+CX3CR1- subset that reside within the LP. Intestinal 
CD103+DCs are migratory and travel to the MLN via the afferent lymph. At steady 
state, the migration of CD103+DCs from the LP to the MLN establishes T cell responses 
specific for harmless luminal antigens, representing an important process for oral 
tolerance. Several DC subsets contribute also to T regulatory generation. In particular, 
the CD8a+ DC subset, promoting Treg generation in the presence of Transforming 
Growth Factor (TGF) β, and the CD103+ DCs.  
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6.4.5.1.1 DCs and gut-homing imprinting on T cells 
An important function of DCs is the ability to imprint homing properties on T cells, in 
order to localize immune responses to a specific tissue. Indeed, T cells activated by 
intestinal DCs but not from splenic or skin-draining LN, acquire the α4β7 integrin and 
CCR9 chemokine expression and home to the intestine [80, 81].  
In particular, only the CD103-expressing DCs have the capacity to induce gut-homing 
molecules on T cells, targeting lymphocytes to intestinal tissue (Figure 8).   
Iwata et al. identified Retinoic Acid (RA), the active metabolite of Vitamin A, as a 
factor capable of instructing the expression of gut-homing receptors during T cell 
priming. The ability of intestinal CD103+ DCs to produce RA is conferred by their 
expression on the RALDH enzymes that oxidize retinal into the active RA. Among the 
classes of RALDH enzymes, RALDH-2 (encoded by aldh1a2) seems to be the most 
predominant enzyme expressed by CD103+ DC of the intestine, MLN and PP [82]. The 
distribution of RALDH-positive DCs correlates with the presence of retinol or RA 
within the body. In agreement, retinol is abundant in the small intestine and the MLN 
compared to the colon and spleen, corresponding to the high frequency of RALDH-
positive DCs in these sites [83].  
T cells that migrate to the small intestine LP express the integrin α4β7 [84] and the 
chemokine receptor CCR9 [85]. The main α4β7 ligand, the mucosal addressin cell 
adhesion molecule-1 (MAdCAM-1), is expressed on intestinal LP venules and the 
CCR9 ligand CCL25/TECK is strongly expressed by epithelial cells in the small 
intestine and in the LP venules. The integrin α4β7 is also critical for T cell migration 
into the colon, even during inflammation. On the contrary, the colon is devoid of 
CCR9+ cells, and particularly, its ligand CCL25 is not expressed.  
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Figure 8: Intestinal DCs imprint gut homing receptors on T cells. Migratory CD103+ 
DCs migrate to the MLN and are exposed to stromal derived-RA and macrophage-
derived GM-CSF, inducing increased expression of DC RALDH-2. In the MLN, RA 
produce by CD103+ DCs induce expression of gut homing receptors, directing T cell 
migration to the small intestine (Adapted from [86]). 
6.4.5.2 Intraepithelial lymphocytes  
The intestinal epithelium contains numerous T cells that are located at the basement 
membrane between enterocytes at a frequency of up to 10-15 intraepithelial 
lymphocytes (IELs) per 100 epithelial cells. They provide the first line of defense 
against infections, preserving the barrier integrity.  
The majority of IELs express the CD8αα glycoprotein that binds to the MHC class I 
(MHC-I) molecule. Intestinal IELs can be divided in two subsets based on TCR 
receptor: αβ TCR or γδ TCR heterodimers. About 50% of IELs express γδ in the small 
intestine, while 40% are positive in the colon [87]. Interestingly, Ismail et al. 
demonstrated that γδ IELs induce the production of innate antimicrobial peptides via the 
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Myeloid Differentiation Primary Response Gene 88 (MyD88) pathway in response to 
harmful pathobionts that penetrate the intestinal epithelium [88].  
6.4.5.3 Lamina propria T cells  
Both CD4+ T cells and CD8+ T cells are found in the intestines, at the approximate ratio 
of 2/1. They may derive from conventional T cells that have been primed in secondary 
lymphoid organs. Indeed, majority of CD4+ and CD8+ T cells display an effector 
memory phenotype in the intestine. Intestinal CD4+ T cells are mostly located in the LP. 
Upon stimulation, naïve T cell can differentiate into four major subtypes: T helper 1 
(Th1), Th2, Th17 or Treg cells [74]. These various CD4+ T cell subsets are 
distinguished by the expression of different transcription factors and cytokines. Several 
studies highlight the important role of gut microbiota in the development of CD4+ T 
cells, within and outside the intestine. Indeed, reduced number of LP CD4+ T cells was 
found in GF mice. Moreover, the spleen and the MLNs of GF mice exhibit defects, as 
lymphocyte zone are absent [89]. 
6.4.5.3.1 T-helper1 cells 
Th1 cells are critically required for appropriate responses to intracellular bacteria and 
viruses. Th1 cells develop via a molecular pathway involving activation of signal 
transducer and activator of transcription 1 (STAT1) and STAT4 by IFNγ and IL-12, 
respectively, which leads to the induction of Tbet, essential transcription factor for the 
development of Th1 cells. Interferons (IFN) are a large family of proteins, which 
include: type I IFN (multiple IFN-α and one IFN-β) responsible for antiviral immunity; 
type II IFN, known as IFNγ, promotes the response to intracellular bacteria; the novel 
family type III IFN (IFN-λ1, IFN-λ2, IFN-λ3 and IFN-λ4) is induced by viral infection 
and shows antiviral activity. Several studies demonstrate that exposure to commensal 
bacteria contributes to drive physiological Th1 development. In agreement, GF mice 
have reduced number of Th1 cells in both mucosal and systemic compartments. This 
reduction in Th1 immunity results in augmented susceptibility to infection with 
different pathogens, such as Shigella flexneri and Listeria monocytogenes [90]. 
Moreover, Bacteriodetes fragilis was shown to induce the development of a systemic 
Th1 response through Polysaccharide A (PSA) molecules [89].   
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6.4.5.3.2 T-helper 17 cells   
Th17 cells are crucial for host defense and have a role in the development of 
autoimmune diseases by producing the proinflammatory cytokines IL-17A, IL-17F and 
IL-22. The development of Th17 cells in mice requires the combination of signals via 
the TCR and from TGF-β1, IL-1β, and STAT3 activating cytokine, such as IL-6 and IL-
21. Unlike other CD4+ T cell subsets, Th17 preferentially accumulate in the intestine, 
indicating that the development of Th17 might be regulated by gut-intrinsic 
mechanisms. Indeed, mice treated with antibiotics and GF mice present reduced 
intestinal Th17 cells [91]. Studies revealed that a particular species of Clostridia-related 
bacteria, called segmented filamentous bacteria (SFB), promotes the generation of Th17 
cells in the small intestine (Figure 9) [92]. In particular, SFB drive Th17 accumulation 
via a serum amyloid A protein-dependent effect, resulting in IL-6 and IL-23 production 
from DCs. Th17 induction by SFB is not entirely benign, because mono-association of 
mice with SFB induced Th17-mediated inflammatory arthritis [93] and multiple 
sclerosis-like symptoms in the experimental autoimmune encephalomyelitis (EAE) [94]. 
Another mechanism described for the generation of Th17 cells involved the luminal 
adenosine triphosphate (ATP), which is provided by commensal bacteria [95]. 
Moreover, the reconstitution of GF mice with the intestinal microbiota of conventional 
mice promotes the development of intestinal Th17 [96]. All these studies highlight the 
critical role of components of the microbiota in the generation of Th17 cells.  
6.4.5.3.3 T Regulatory cells 
T Regulatory Cells (Tregs) accumulate in the intestine and are essential for maintaining 
the gut homeostasis by preventing inappropriate innate and adaptive immune responses. 
Regulatory CD4+ T cells include subsets distinguishable on the basis of their expression 
of the transcription factor Foxp3: Foxp3+(Treg) or Foxp3- (T regulatory cells 1 (Tr1)). 
Most CD4+Foxp3+ Treg cells originate in the thymus under the influence of adequate 
TCR stimulation. Further development requires signals from the costimulatory molecule 
CD28 and common γ chain cytokines, including IL-2 and IL-15, to activate STAT5 and 
induce Foxp3 expression [97]. After exiting the thymus, some Treg cells migrate to the 
intestine, where they recognize intestinal antigens and prevent inappropriate immune 
responses. However, the intestine contains a large number of non-thymically derived 
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Foxp3+ iTreg cells. Indeed, naïve CD4+ T cells can differentiate into induced Foxp3+ 
Treg (iTreg) cells when activated by transient TCR stimulation or TCR stimulation in 
the presence of TGF-β and IL-2. IL-10 represents the immunosuppressive cytokine 
crucial for the regulatory properties of Treg cells. In the colon, Foxp3+Treg cells are the 
almost exclusive T cell source of IL-10 while in the small intestine, both Foxp3+ Treg 
and Tr-1 cells produce IL-10. Importantly, Tr1 cells display their suppressive function 
via the production of IL-10 and TGF-β. Moreover, the maintenance of the Treg 
population is also different in the large and small intestine. Indeed, Treg cells are 
maintained in the small intestine of GF mice [98]. On the contrary, the presence of Treg 
cells in the colon is highly dependent on the presence of the gut microbiota, being 
significantly reduced in GF conditions and by antibiotic-treatment. Specific populations 
of commensal bacteria have been found to expand Treg cells in the colon (Figure 9). In 
particular, the Treg accumulation is promoted by the colonization of GF mice by one of 
these bacterial populations: a mixture of 46 Clostridium spp. Cluster IV and XIVa 
strains [99]; altered Schaedler flora (ASF) consisting in a mixture of eight commensal 
bacteria [100] and the human commensal bacteria B. fragilis [101]. Moreover, several 
studies highlight the important role of short-chain fatty acids (SCFAs) derived from gut 
commensals metabolism in inducing Treg differentiation and accumulation. In 
particular, Garret et al. demonstrated that oral administration of SCFAs (including 
butyrate, acetate and proprionate) in GF mice increases Treg number in the colon, but 
not in other lymphoid organs [102]. Further studies showed that butyrate could 
downregulate the production of proinflammatory mediators (including IL-6, nitric oxide 
(NO) and IL-12) from LP macrophages, via inhibiting histone deacetylases, underlying 
the importance of butyrate in the maintenance of tolerance to microbiota [103]. 
Importantly, Kawamoto et al. showed that Foxp3 cells contributed to the diversification 
of the gut microbiota.  In particular, Treg cells repress inflammation and support IgA 
selection in the germinal centers (GCs) of PPs. Indeed, diversified and selective IgAs 
are crucial for the maintenance of balanced intestinal microbiota [104].   	
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Figure 9: Intestinal microbiota shapes T cell immunity.  SFB and other commensal 
bacteria activate LP DCs and macrophages to induce Th17 and Th1 cells thought the 
production of several chemokines (IL-6, IL-1β and IL-23). Clostridium spp. clusters IV 
and XIVa, PSA+ B. fragilis and other commensal bacteria stimulate the generation of 
Treg cells (Adapted from [105]).  
6.4.5.4 IgA-producing B cells and plasma cells  
IgA is the major class of immunoglobulins produced in mucosal tissue, including the 
intestine. In the intestinal lumen, IgA is produced as polymeric IgA at high 
concentrations. Polymeric IgA is transported via pIgR that is expressed on intestinal 
epithelial cells and is released into the intestinal lumen as secreted IgA (SIgA). 
Remarkably, SIgA coat commensal bacteria and soluble antigens, inhibiting their 
binding to the intestinal epithelium and their penetration into the LP, and neutralize 
toxin and pathogens without causing inflammation due to its ability to inactivate the 
complement cascade [106]. In addition, SIgA promote the establishment of a 
mutualistic host-microbe relationship, by downregulation of proinflammatory epitopes 
by microbes. Moreover, SIgA neutralizes microbial compounds with proinflammatory 
activity (such as Lipopolysaccharide, LPS) and facilitates the formation of a biofilm that 
favors the growth of commensals while attenuating that of pathogens. Intestinal plasma 
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cells that produce IgA can be generated by both T-dependent and T-independent 
mechanisms (Figure 10): 
T cell dependent induction of IgA+ B cells: IgA+ B cells are mostly generated in the GCs 
of PPs by activation of B cells and induction AID, a key enzyme required for CSR and 
SHM. Mechanistically, DCs uptake luminal antigens and migrate to the T cell-zone, 
where they induce the differentiation of CD4-expressing T cells in T-follicular helper 
cells (TFH). CD40L and IL-21 by TFH induce the expression of AID in B cells and 
promote the IgA-CSR. Then, IgA+ plasmablasts migrate from the PPs to the gut LP 
where they further differentiate into IgA plasmacells that secrete IgAs [107].  
T cell independent induction of IgA+ B cells: Unlike in PPs, the generation of IgA+ cells 
in the LP and in ILFs does not require T cells or the GC formation. Many DCs, possibly 
CX3CR1+ DCs, take up luminal antigens and activate B cells. Several factors released 
by DC and macrophages facilitate the class switching of B cells to IgA+ B cells. In 
particular, Tumor Necrosis Factor (TNF) α induces the expression of metalloproteinases 
(MMPs), which mediate the conversion of TGF-β1 from inactive to active form. 
Together with BAFF and a proliferation inducing ligand (APRIL), active TGF-β1 
facilitates the CSR to IgA [107].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
46 
	
 
 
 
 
 
 
 
 
 
 
 
Figure 10: Intestinal plasma cells that produce IgA can be generated by both T-
dependent and T-independent mechanism. (A) In T cell dependent IgA production, 
DCs induce the differentiation of naïve T cells to TFH. B cells, which are stimulated by 
activated T cells, express CD40L and several cytokines necessary for the induction of 
AID and CSR. (B) On the contrary, in T cell independent IgA production, AID is induce 
by innate mechanisms, including TLR signaling, APRIL and BAFF, which are produced 
by DCs (Adapted from [108]).    
IgA has been shown to regulate the composition and the function of the gut microbiota. 
Dysfunction in the IgA compartment as a result of deficiency in AID, leads to alteration 
in the composition of the intestinal microbiota. The gut microbiota also regulates IgA 
production, as demonstrated by the reduction of IgA number in GF mice. Moreover, 
commensal bacteria instruct LP DCs to induce the differentiation of IgA-producing B 
cells. In particular, bacterial-derived flagellin promotes the synthesis of RA, which is an 
essential molecule that facilitates the differentiation of IgA-producing B cells by 
intestinal DCs. In addition, gut microbiota promotes the expression of factors that are 
involved in the induction of IgA+ B cells, such as TNF, inducible nitric oxide synthase 
(iNOS), BAFF and APRIL in LP DCs (Figure 11). Moreover, intestinal plasma cells 
express TNF and iNOS after microbial exposure and promote the IgA secretory 
function of B cells [109].      
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Figure 11: Intestinal microbiota promote the generation of IgA-producing B cells and 
plasma cells. TLR activation on IECs induces the production of BAFF and APRIL, 
promoting the differentiation of IgA-producing plasma cells. IECs also produce thymic 
stromal lymphopoietin (TSLP) to promote BAFF and APRIL expression by DCs. 
Various types of DCs secrete BAFF, APRIL, NO, RA and TNF to facilitate the 
expression of AID and IgA class switching in B cells (Adapted from [105]).     
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6.4.6 Role of intestinal microbiota in IBD 
In the GI tract, several immunoregulatory mechanisms prevent the unnecessary 
activation of the immune system against innocuous antigens including those expressed 
by commensal bacteria. A breakdown of these regulatory mechanisms results in a set of 
chronic inflammatory conditions, known as Inflammatory Bowel Disease (IBD), 
encompassing Crohn Disease (CD) and Ulcerative Colitis (UC) (Figure 12). A mixture 
of genetic factors, the host immune system, environmental factors as well as the 
microbiota contribute to the etiology of the disease. IBD is associated to important 
changes of the intestinal microbiota; in particular, several studies have shown that both 
CD and UC are associated to reduced complexity of the gut microbiota and consistent 
shifts to dysbiotic conditions. Both CD and UC are characterized by an expansion of the 
phyla Proteobacteria and in particular of the Enterobacteriaceae family [110]. 
Moreover, several inflammatory commensals, such as adherent-invasive Escherichia 
coli, Yersinia and Clostridium difficile, are much more common in patients with CD 
compared to healthy individuals [111]. Furthermore, several commensal bacteria that 
are typically found in low abundance, can acquire pathogenic properties. Indeed, E.coli, 
which is innocuous at steady state condition, is able to use inflammatory NO generated 
by immune responses as an energy source, acquiring a significant growth advantage 
[112]. Other bacteria, called Bilophila wadsworthia, take advantage of dietary induced 
bile acids to dominate the intestine, contributing to the intestinal disease [113]. Studies 
revealed also the capacity of the intestinal flora in influencing IBD. In fact, mice 
deficient in both Tbet and adaptive immunity develop a spontaneous and transferrable 
form of ulcerative colitis (TRUC mice) [114]. The transfer of the microbiota from 
TRUC mice to wild-type mice recipients also transfers the colitis. In particular, several 
species of commensal bacteria such as Proteus mirabilis, Klesbiella pneumoniae or 
Helicobacter typhlonius are increased in the intestine of TRUC mice and can transfer 
the colitis to wild-type mice [115, 116]. Another important factor in the induction of 
IBD is the loss of symbiotic commensal bacteria that rely upon fermentation as their 
energy source. Studies revealed that the bacteria of the phylum Firmicutes and in 
particular the class Clostridia are reduced in patients with IBD [110]. In fact, Clostridia 
are essential bacteria to generate colonic Tregs, that can oppose colitis induction [99]. 
Moreover, the diet has an important effect on the microbiota composition, leading to the 
49 
	
expansion of pathobionts. For instance, a diet rich in saturated milk fats induces 
dysbiosis and the expansion of Bilophila wadsworthia, promoting Th1 immune 
response and exacerbating colitis in Il10-/- mice but not in wild-type mice [113]. Taken 
together, these observations suggest that the intestinal immune system is shaped by 
commensal dysbiosis in two different ways. First, by the outgrowth of opportunistic 
bacteria that drive intestinal inflammation, and second, by the loss of benign fermenting 
bacteria which produce essential metabolites for immunoregulatory functions.  
 
 
 
 
 
 
 
 
 
 
 
Figure 12: Inflammatory and anti-inflammatory properties of intestinal microbiota in 
IBD. Beneficial commensal microbiota protects the intestinal mucosa thought the 
induction of Treg cells, IL-10 and the antimicrobial peptide Reg3γ. In IBD, a 
combination of genetic and environmental factors results in a disruption of the 
microbial community, leading to dysbiosis. This condition causes a loss of beneficial 
bacteria and/or accumulation of pathogenic bacteria, leading to chronic inflammation 
mediate by Th1/Th17 cells (Adapted from [105]).    
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6.4.7 Microbiota and extra-intestinal diseases 
The microbiota may also contribute to autoimmune diseases at extra-intestinal sites 
(Figure 13). Studies in animal models suggested that host immune responses are Th2-
biased under GF conditions. In particular, GF mice or antibiotic-treated mice show an 
expansion of basophils in the peripheral blood and increased serum IgE levels. Cystic 
fibrosis (CF) is also modulated by gut microbiota. The pathogenesis of Rheumatoid 
Arthritis (RA) is influenced by the intestinal microbiota. Studies in animal models 
indicated that gut microbiota contributes to disease symptoms. In fact, arthritis 
symptoms are reduced in K/BxN transgenic mice in GF condition. Moreover, Th17 cell 
response are implicated in promoting disease, and SFB-mediated enhancement of the 
Th17 cell immunity, stimulating autoantibody production by B cells, promote the 
disease [93]. In addition, analysis of the microbiome in patients suffering RA confirmed 
a correlation between the disease and the pro-inflammatory members of Prevotellaceae 
family [117]. Furthermore, the impact of the microbiota in inducing Multiple Sclerosis 
(MS) has been largely investigated. In particular, the incidence of disease in the mouse 
model of Experimental Autoimmune Encephalitis (EAE) is also dependent on the 
commensal microbiota. Accordantly, the development of the disease varied among 
genetically identical mice housed in different animal facilities. Furthermore, studies 
showed that the activation of myelin-specific B cells and the invasions of the neurons 
by T cells require intestinal microbiota [118]. By contrast, several commensal bacteria 
are capable of attenuating inflammation in the central nervous system (CNS). For 
example, PSA+ B. fragilis can prevent EAE symptoms, inducing Treg cell 
differentiation [119].  The intestinal microbiota can also provide protection against 
some inflammatory diseases. For example, the incidence of disease in the Non-Obese 
Diabetic (NOD) mouse model of Type 1 Diabetes (T1D) is high in GF mice and the 
presence of SFB induces protection from the disease [120]. 
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Figure 13: Intestinal microbiota affects autoimmune diseases at extra-intestinal sites. 
Increased intestinal Th17 promote the expansion of pathogenic autoantigen-specific T 
cells, causing inflammation in the CNS. On the contrary, beneficial commensal bacteria 
can attenuate CNS inflammation, inducing Tregs generation. Moreover, microbiota-
induced IL-1β signaling participates to the development of RA through the induction of 
Th17 cells. In addition, attenuated risk of T1D is associated to decreased 
Firmicutes/Bacteroidetes ratio as well as deficiency in MyD88 signaling in non-obese 
diabetic mice. Finally, microbial compounds stimulate peripheral B cells, inhibiting IgE 
production. Decreased IgE levels result in reduced number of basophils and 
consequently, attenuated risk of allergic airway inflammation (Adapted from [105]).   
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6.5 The Skin compartment 
6.5.1 Skin manifestations in PIDs 
Cutaneous manifestations are common in PIDs, affecting between 40% and 70% of 
patients with diagnosed PIDs. Skin infections characterize several PIDs, but more 
frequently noninfectious cutaneous manifestations have been found in many of these 
disorders, including cutaneous granuloma, dysplasia of skin, hair, and nails, eczematous 
lesions, autoimmune conditions and frank vasculitis [121]. 
Skin infections involving bacteria include folliculitis, abscesses, furunculosis, impetigo, 
or pyoderma gangrenosum. Among disorders of phagocytosis, CGD present frequent 
bacterial infections, with suppurative adenitis in 53% of patients and subcutaneous as 
well as liver abscess due to Staphylococcus being the most common [122]. Bacterial 
skin infections are also a prominent feature of the hyper-IgE syndrome, due to a STAT3 
deficiency, or the dedicator of cytokinesis protein 8 (DOCK8) deficiency. Severe 
recurrent abscesses with Staphylococcus aureus particularly localized on the scalp, face 
and neck, characterized the disease [123]. Atopic dermatitis or eczematous lesions 
seems to be the second most common presentation in PIDs. In particular, eczema occurs 
in 71% of patients with WAS [124]. Moreover, the erythematous rash in OS is often 
described as erythroderma and patients tend to have alopecia with loss of eyebrows and 
eyelashes [25]. Other skin manifestations are often reported in PIDs. Particularly, the 
skin may also be a site of the granulomatous lesions in CGD [125]. Patients with 
mutations in the early complement factors (C1, C2, C4) often present photosensitive 
malar rash and mucocutaneous vasculitis typical of systemic lupus erythematous. 
Autoimmune dermatomes such as vitiligo and alopecia are present with increased 
prevalence in several adaptive PIDs, including SCID [126, 127] and IgAD [128]. 
Moreover, cutaneous autoimmune manifestations such as vitiligo and alopecia 
characterized the autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy 
(APECED), a genetic disorder due to a mutation in Aire gene [129].  
Recently, Oh et al. characterized the bacterial and fungal microbiota of several groups 
of PID, including hyper-IgE deficiency, WAS syndrome and DOCK8 syndrome. All 
individuals with these PIDs exhibit skin eczema. The study demonstrated an increased 
permissivity in the bacterial and fungal colonization of the skin of PID patients, 
dysbiosis and strong association with skin disease manifestations and severity. 
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Specifically, these patients present increased representation of fungi that can develop as 
opportunistic pathogens, including Candida albicans and Aspergillus sprecies (spp). 
Based on these results, it has been hypothesized that PIDs increase the host’s ability to 
be colonized by atypical microbiota [130].  
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6.5.2 Skin anatomy and physiology 
The skin is a complex organ that acts as a chemical and physical barrier to protect the 
body from infection and penetration of toxic agents. The human skin, with its surface 
area of 1.8 m2, is composed of the epidermis, attached to basement membrane, 
underlined by the dermis and a subcutaneous fatty region. Specialized epithelial cells, 
called keratinocytes, compose the stratified layers of the epidermis. The outermost layer 
of the epidermis, the stratum corneum, is characterized by dead keratinocytes, called 
corneocytes, functioning as a barrier to exclude many toxic agents and avoid 
dehydration. This is followed by the stratum granulosum, containing tight junctions and 
the stratum spinosum. Lastly, the basal stratum constitutes the bottom layer of the 
epidermis and is responsible for constantly renewing the cells of the epidermis. This 
stratum is attached to a complex basement membrane (Figure 14). Importantly, the 
upper layers of the epidermis are composed by keratinocytes in cell division. The 
progeny of these cells move upwards as they differentiate and eventually die [131].  
The epidermis contains dispersed cell type called Merkel cells, which stimulate nervous 
system [132], and melanocytes, which are important for protection against ultraviolet 
light damage. Specialized cells of the epidermis include also Langerhans cells, the main 
skin resident immune cells, and T cells, mainly CD8+ T cells, resident in the stratum 
basal and stratum spinosum.  
The dermis is characterized by a network of fibroblasts that produces a collagen-rich 
extracellular matrix. In addition, the presence of blood and lymphatic vessels in the 
dermis allows the trafficking of immune cells. Many specialized cells, including DCs, 
αβ T cells, γδ T cells and NK cells reside in the dermis.   
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Figure 14: Structure and anatomy of the human skin. It is composed by two layers: 
epidermis and dermis. Epidermis is a stratified squamous epithelium which is divided in 
four layers: stratum corneum, stratum granulosum, stratum spinosum, and stratum 
basale  (Adapted from [133]). 
6.5.3 Skin microbiota 
The skin contains about 1012 resident bacteria/m2. Most skin bacteria can be divided in 
four different phyla: Actinobacteria, Firmicutes, Bacteroidetes and Proteobacteria. 
Importantly, the skin microbiota is dependent on the body areas (Figure 15); in 
particular, the colonization of bacteria is dependent on the physiology of the skin site, 
with specific bacteria being associated with moist, dry and sebaceous environment. 
Indeed, bacterial diversity seems to be lowest in sebaceous sites and Propionibacterium 
spp are the dominant microorganisms in these areas. On the contrary, Staphylococcus 
and Corynebacterium spp are the most abundant in the moist areas, suggesting that 
these bacteria prefer high humidity environments. Mixed representations from the phyla 
Actinobacteria, Firmicutes, Bacteroidetes and Proteobacteria colonize the dry areas of 
the body [134].  
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Figure 15: Distribution of bacteria on skin sites. The skin microbiota diversity is 
highly dependent on the body areas, divided in moist, dry and sebaceous (Adapted from 
[134]).  
6.5.4 Innate immune barrier in the skin  
In the skin compartment, the physical and biochemical barrier consists in a combination 
of terminally differentiated keratinocytes and the acidic, hydrophilic composition of the 
skin, as the results of sebum, lipids and AMPs production [135]. In addition, innate 
immune cells such as polymorphonuclear leucocytes (PMN), monocytes and 
macrophages, DCs and NK cells contribute to the cutaneous innate immune defenses.   
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6.5.4.1 Keratinocytes 
Keratinocytes can sense pathogens and discriminate between commensal organisms and 
harmful bacteria. They represent the major cell type in the epidermis, constituting more 
than 90% of epithelial cells. They express several pattern recognition receptors, 
including TLRs recognizing a great variety of pathogens and self-components (Figure 
16), NLRs, which respond to bacterial peptidoglycan, and NLR pyrin domain-
containing proteins that respond to viral, fungal and self-compounds. Moreover, the 
expression of RLRs allows the response to viral RNA whereas C-type lectins, such as 
Dectin-1, detect fungal infections.   
In response to microbial sensing, keratinocytes can produce several antimicrobial 
peptides (AMP): LL-37, β-defensins (HBDs), RNAses, and S100 family members. 
Importantly, during skin infection, the local production of AMPs by keratinocytes can 
be amplified by T cell-derived cytokines, such as IL-17A and IL-22 [136]. In addition 
to AMPs, keratinocytes release numerous cytokines, including IL-1, IL-6, IL-10, IL-18 
and TNF. Moreover, keratinocytes represent an important source of chemokines and 
express chemokine receptors, modulating immune responses by attracting several cell 
types to the skin. By expressing CC-chemokine-ligand 20 (CCL20), CX-chemokine 
ligand 9 (CXCL9), CXCL10, CXCL11, keratinocytes can attract T cells to the 
cutaneous compartment. Moreover, keratinocytes regulate the trafficking of Langerhans 
cell precursors to the epithelium thought the expression of CCL20 [137]. In the 
epidermis of patients with psoriasis, keratinocytes can also recruit neutrophils by 
producing CXCL11 and CXCL8 [138].  
Importantly, keratinocytes can act also as non-professional antigen presenting cells 
(APCs). In fact, several studies showed that keratinocytes express MHCII molecules in 
different skin disorders, especially characterized by T cell infiltrates [139].  
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Figure 16: Microbial recognition and activation by keratinocytes. Keratinocytes 
recognize foreign and dangerous agents, including irritants and toxins through TLRs 
and the inflammasome machinery. In particular, microbial recognition by TLRs induces 
the activation of several cellular pathways, necessary for the release of chemokines, 
cytokines and antimicrobial peptides. Moreover, following exposure to stimuli, such as 
UV irradiation, keratinocytes release the active form IL-1β through the activation of the 
inflammasome (Adapted from [140]).        
6.5.4.2 Antimicrobial peptides 
	
Antimicrobial peptides (AMPs) bind membranes of microbes through their hydrophobic 
surface and form pores in the membrane, resulting in microbial killing. The most 
important keratinocyte-derived AMPs in human skin are the β-defensins (HBD)-1, 
HBD-2 and HBD-3. HBD-1 is constitutively expressed in human epidermis and exhibit 
antimicrobial activity against Gram-negative bacteria. On the contrary, HBD-2 can be 
induced by inflammatory mediators such as TNFα, IL-1 and several microbial 
components and showed efficacy against Gram-negative bacteria. HBD-3, inducible 
HBD, demonstrated potent bactericidal activity against the Gram-positive pathogens. 
The cathelicidin LL-37 showed pronounced antibacterial, antifungal and antiviral 
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activity. LL-37 has a central role also in several skin disorders. In atopic dermatitis, LL-
37 levels are reduced, explaining the predisposition of atopic skin to bacterial 
infections. Moreover, altered processed peptides of cathelicidin are found in rosacea 
lesions, contributing to cutaneous inflammation. Another important AMP that induces 
the permeabilization of bacterial membranes is psoriasin (S100A7). It plays a central 
role in killing E. coli and is a potent chemo attractant for CD4+ T cells and neutrophils. 
Studies revealed that the expression of some AMPs can be controlled by specific 
members of the microbiota, such as Prionibacterium spp.[141].  
6.5.4.3 Dendritic cells 
Initiation of the adaptive immune responses requires pathogen-derived antigen capture, 
processing and presentation by DCs. In the skin, DCs are divided in three distinct 
subsets: Langerhans cells, found in the epidermis, and two dermal populations, 
CD11b+DCs (CD1c+ DCs in humans) and CD103+ DCs. In particular, CD103+ dermal 
DCs are members of the CD8+ DC-like group and are important for CD8+ T cell 
responses and viral immunity. These cells express molecules directed to recognition of 
viral and other intracellular pathogens, produce IL-12 to drive Th1-cell type immunity 
and are efficient at cross-presenting antigens for the induction of CD8+ T cell responses. 
The role of CD11b+ DCs in mouse skin immunity has not been defined, although they 
have been linked to Th17-mediated immunity in other tissues. Indeed, after skin 
infection with herpes simplex virus (HSV), CD11b+ DCs present antigens preferentially 
to CD4+T cells. A study divided the CD11b+ dermal DCs based on the expression of 
ALDH, demonstrating that ALDH+ DCs may convert retinol to RA that drive Treg cell 
generation [142]. Langerhans cells are positioned in the epidermis above the basal 
keratinocytes and project their dendrites upward toward the cornified epithelial layer. 
These dendrites are able to sample antigens within the cornified layer without damaging 
the epidermal integrity. Recently, several studies highlighted that Langerhans cells 
contribute to priming immunity to skin pathogens such as C. albicans and S. aureus, 
favoring induction of Th17-mediated responses [143]. In contrast, Langerhans cells 
have a poor capacity to induce CD8+ T cells, as shown for CD103+ DCs. It was also 
described the immunosuppressive role of Langerhans cells, by inducing T cell deletion 
or by activating Treg cells to dampen skin immune responses. Plasmacytoid DCs (pDC) 
are only moderately efficient presenting cells but represent the major source of type I 
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IFN. They circulate in the blood and are basically absent from human skin. However, 
they are recruited during inflammatory conditions such as viral infection, allergy or 
autoimmunity. 
6.5.4.3.1 DCs and skin homing imprinting on T cells 
DCs from skin-draining lymph nodes (DLNs) specifically imprint skin homing 
receptors on activated T cells. The T cell localization in the skin requires the expression 
of cutaneous lymphocyte associated antigen (CLA). CLA mediates the tethering and the 
rolling of T cells through the interaction with its endothelial receptor E-selectin, 
expressed normally on skin post-capillary venules. However, other skin molecules have 
been implicated in the homing process. For instance, the interaction between CCR4 and 
its ligand CCL17 (TARC) has been implicated in skin homing of immune cells; in 
particular, CCR4 is necessary for antigen-driven accumulation of CD4+ T cells under 
physiological conditions [144]. Moreover, interaction between CCR10 and its ligand 
CCL27 (CTAK) has also been implicated in skin homing [145]. Recently, vitamin D 
has been proposed to have a key role in the guidance of memory T cells through the 
upregulation of the receptor CCR10 [146]. 
6.5.5 Skin T cells 
Lymphocytes are present in significant numbers in human skin, while B cells are rare. 
Indeed, human healthy skin contains more than 2x1010 skin resident T cells. Epidermal 
T cells are mainly distributed at the basal and suprabasal keratinocytes layer, in close 
contact with Langerhans cells. In the dermis, T cells are preferentially clustered around 
postcapillary venules and are often situated just beneath the dermal–epidermal junction 
or adjacent to cutaneous appendages. Conventional T cells, known as αβ T cells, reside 
in the skin and the majority presents a memory phenotype. Unconventional T cells, 
called γδ T cells, reside mainly in the epidermis (Figure 17).  
6.5.5.1 αβ T cells 
Human skin contains a large numbers of αβ T cells, with a memory phenotype. These 
cells consist of both CD4+ and CD8+ subsets, with about 10% of the CD4+ T cells 
expressing Foxp3, indicating a Treg cell phenotype. CD8+ T cells are predominantly 
localized in the epidermis while CD4+ T cells in the dermis. Interestingly, the epidermal 
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CD8+ cells persist for long period in the skin and are known as tissue resident memory 
T cells (TRM). During cutaneous inflammation or infection, effector CD8+ T cells enter 
in the dermis from the blood and migrate to the epidermis through the chemokine 
receptor CXCR3 [147]. Several signals found within the epidermis instruct CD8+ T 
cells to develop TRM via the upregulation of molecules, such as CD103 and CD69, and 
the downregulation of sphingosine-1-phospate receptor 1 (S1PR1), required for tissue 
exit. Notably, CD8+ TRM cells protect mice against skin infection with viruses [148]. In 
contrast to CD8+ T cells, a proportion of memory CD4+ T cells is able to migrate into 
the circulation and is known as T effector memory cells (TEM cells) [149]. However, 
many remain in the skin and express markers of TRM cells, such as CD103 and CD69. In 
agreement, about a half of the CD4+ T cells in the skin lack the expression of CCR7, a 
chemokine receptor necessary for the migration to the LN [150]. 
Three many subsets of CD4+ T cells, such as Th1, Th17 and Th2, have been identified 
in the skin during inflammatory conditions. The Th1 responses are associated with 
autoimmunity and immune–mediated diseases, like psoriasis, whereas Th2 responses 
are linked to allergic diseases, such as atopic dermatitis and acne. Recently, Th17 
responses have been described to exert a potential role in the pathogenesis of both 
psoriasis [151] and atopic dermatitis [152]. 	
6.5.5.2 γδ T cells 
The epidermis contains γδ T cells that represent all the epidermal T cells in mice, 
known as dendritic epidermal T cells (DETCs), while they constitute a minor subset in 
humans. DECTs express a conserved Vγ5 Vδ1 TCR and are constitutively clustered on 
dendritis forming polarized anchors at epithelial tight junctions.     
DETCs exhibit slow homeostatic division under steady state conditions and need 
exogenous IL-15 and IL-2Rβ for proliferation and survival. They have been shown to 
participate in would healing and contribute to inflammation, tumor surveillance, contact 
hypersensitivity and antibacterial response. Studies demonstrated that wounds without 
DETCs show impaired keratinocyte proliferation, reduced inflammation and slower 
closure [153]. Activated DETCs express a large variety of chemokines and cytokines, 
such as CCL3, CCL4, CCL5 and XCL1, IFNγ, IL-2 and IL-13. In addition to the 
presence of DETCs in the epidermis, mice present a large Vγ5-Vγ4+ population of γδ T 
cells in the dermis. The dermal γδ T cells do not require IL-15 for survival but need IL-
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7. Moreover, the majority of dermal γδ T cells expresses CCR6 and produce IL-17. In 
particular, this population has an important role in the imiquinod-induced model of 
psoriasis. In agreement, psoriatic patients showed increased numbers of IL-17-
producing γδ T cells in their skin [154]. Several studies have investigated the possible 
link between skin microbiota and γδ T cells, underling the reduced ability of these cells  
to produce IL-17 in mice devoid of live bacteria [155].  
 
Figure 17: Overview of the main populations located in the skin. The mouse epidermis 
is populated by three important immune cell types: Langerhans cells, DETCs and CD8+ 
TRM cells. The dermis contains: Treg cells, CD4+ TRM cells, CD4+ TEM cells, other γδ T 
cells, innate lymphoid cells (ILCs) and several DC populations (Adapted from [156]). 
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6.5.6 Association of the microbiota with inflammatory skin disorders 
The commensal bacteria protect the skin from infections by competing pathogens and 
contribute to immune homeostasis by modulating cutaneous immune responses in 
beneficial and harmful ways. On the other side, the immune system releases several 
antimicrobial peptides to control the microbial colonization of the skin. Cutaneous 
commensal bacteria can control skin resident T cell function and protective immunity to 
pathogens. During the infection with the parasite Leishmania major, the presence of S. 
epidermidis is necessary for IFNγ and IL-17A production by skin resident T cells and 
for protective immunity [155].  
Moreover, studies reported that skin colonization with S. aureus triggers local allergic 
responses by releasing δ-toxin, which directly induces the degranulation of dermal mast 
cells, promoting adaptive and innate Th2 immune responses [157]. Skin bacteria can 
also contribute to the pathogenesis of several skin disorders, such as psoriasis, atopic 
dermatitis, and acne. Indeed, S. aureus, a common cause of skin disease, is frequently 
found in the skin of patients with atopic dermatitis [158]. More specifically, the relative 
abundance of S. aureus and also the skin commensal Staphylococcus epidermis increase 
with clinical disease activity. Iwase et al. suggested that increased abundance of S. 
epidermis reflects a microbial response to S. aureus overgrowth [159].  Moreover, 
increased bacterial diversity end enrichment in Streptococcus spp was detected in 
lesional psoriasis [160]. Additionally, the skin of patients that are affected by acne 
vulgaris is dominated by a single bacterium, Propionibacterium acnes [161]. Studies on 
the skin of PID patients revealed altered indigenous microbiota composition, with 
colonization of several microbial species not observed in healthy controls, such as 
Clostridium species and Serratia marcescens [130].  
However, commensal bacteria are not only the unique source of disease state, but 
additional triggers, such as genetic predisposition and/or infections could contribute to 
the development of the disease. In particular, variations of the skin barrier and 
consequent cutaneous penetration of microbes play an important role in triggering skin 
diseases. For instance, mutations in the epidermal expressed filaggrin (FLG) gene are 
associated to atopic dermatitis [162]. Moreover, deficiency in disintegrin and 
metalloproteinase domain-containing protein 17 (ADAM-17) was sufficient to induce 
the expansion of Corynebacterium bovis and S. aureus in mice, contributing to enhance 
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atopic dermatitis [163]. Finally, in the context of metabolic disorders, chronic 
inflammatory state and altered nutrient availability could contribute to the emergence of 
several bacteria that induce local inflammation (Figure 18).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18: Mechanisms through which skin microbiota might initiate or amplify 
cutaneous disorders. The capacity of the skin microbiota to promote disease could 
depend by host genetic predisposition, metabolic disorders, altered barrier integrity 
and infections (Adapted from [164]). 
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7. AIM OF THE STUDY 
	
Omenn syndrome is a complex disease in which immunodeficiency is associated with 
autoimmune manifestations that can manifest in the form of an inflammatory bowel 
disease-like illness and cutaneous degeneration. Although the identification of the 
molecular bases of OS has allowed the precise diagnosis of the disease, the mechanisms 
underlying autoimmunity are still puzzling and difficult to explore in OS patients. In 
literature, compelling evidence indicates the critical role played by the environment 
(physical insults, toxins, nutrition and microorganisms) in the induction of autoimmune 
disease. In particular, pathogenic, pathobiotic and commensal microorganisms have 
been shown to influence the disease progression in genetically susceptible hosts. In this 
regard, one of the most intriguing and still unsolved question regarding OS disease is 
whether the source of the (limited) immunophenotypic variation in patients, ranging 
from leaky forms of severe combined immunodeficiency to full blown forms with 
severe autoimmunity, depends on defects in the gut-blood barrier, which may render OS 
patients susceptible to inflammation sustained by endogenous commensal flora, whose 
antigens might be recognized by homeostatically proliferating peripheral oligoclonal T 
cells. Moreover, in OS, iatrogenic components altering the commensal microbiota (e.g., 
prolonged courses of antibiotic) may interfere with immunological tolerance by 
affecting the development of functional regulatory T cells. Thus, in this thesis I aim to 
investigate the extent to which alterations in the homeostasis of the intestinal tract, the 
largest body surface in contact with the external environment and key component of the 
host defence against pathogens affected by a constant interaction between resident 
microbes and the immune system, influences the pathogenesis of autoimmune 
manifestations. Thanks to the availability of the Rag2R229Q/R229Q mouse, which faithfully 
recapitulates the human disease, I plan to define the cellular and molecular bases 
underlying the intestinal inflammation in OS and to challenge the hypothesis that a 
dysregulated adaptive and/or innate immune response to the commensal bacterial flora 
plays a central role in disease pathogenesis, causing both local and systemic 
autoimmunity, particularly the skin manifestations. To this end, I will pursue the 
following aims: 
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Aim 1. To study the intestinal pathology in Rag2R229Q/R229Q mice 
• To determine the cellular and molecular bases of the altered intestinal immune 
homeostasis in Rag2R229Q/R229Q mice 
• To investigate whether T regulatory impairment contributes to intestinal 
inflammation in OS 
• To assess whether B cell compartment could be crucial for maintaining intestinal 
homeostasis and avoid bacterial translocation  
• To explore the role of gut microbiota on intestinal and systemic autoimmunity in 
the OS pathogenesis 
Aim 2. To study the skin degeneration in Rag2R229Q /R229Qmice 
• To characterize the cellular and molecular bases of the altered cutaneous 
homeostasis in Rag2R229Q/R229Qmice 
• To investigate dysfunctions of the skin barrier integrity in OS pathogenesis 
• To explore the contribution of altered gut permeability and inflammation in OS 
skin degeneration 
 
Data obtained in these aims are expected to highlight the pathogenic mechanisms 
basically involved in the induction of IBD-like and skin disorders in OS; hence, they 
may have further implications for the development of treatment strategies for this 
immunodeficiency that may utilize improvement of colitis and skin disease as a 
measure of clinical efficacy. Moreover, these findings will help to define the extent to 
which intestinal inflammation may impinge on the overall clinical disease phenotype, 
with particular attention to the outcome of autoimmune manifestations. I expect to 
understand if and to what extent an altered composition of intestinal microbiota in the 
Rag2R229Q/R229Q mice directs the type of mucosal and systemic immune responses by 
affecting the balance between pro-inflammatory and anti-inflammatory cell populations. 
These findings would help to reveal and recognize a novel and important aspect in the 
pathogenesis of OS and other forms of immunodeficiency associated with both 
intestinal and cutaneous diseases. Moreover, results from this thesis will have more 
broad implication in fundamental immunology contributing to gain insight into the 
molecular mechanisms underlying the microbiota-mediated fate determination of T 
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cells. Finally, they will also provide new foundations for the design of novel immuno- 
or microbe-based therapies. 
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8. MATERIALS AND METHODS 
	
8.1 Mice used in the study  
129Sv/C57BL/6 knock-in Rag2R229Q/R229Q mice (hereafter of Rag2R229Q mice) were 
backcrossed to C57BL/6J strain for four generations. This resulted in chimeric mice 
with genetic background very close (85% as determined by SNPs analysis) to C57BL/6J 
strain. The colony was maintained in heterozygosity and littermates were kept in the 
same cage until weaning. Rag1−/− (Rag1tm1Mom/J) mice were obtained from The Jackson 
Laboratory and C57BL/6 Ly5, OT-1 and OT-II mice from Charles River. 
Rag2R229QMyd88−/− double-mutant mice and littermate controls were generated from 
heterozygous–heterozygous crossing. All mice were housed in a specific pathogen-free 
facility. Both male and female mice aged between 8-12 weeks (as indicated) were used 
in the study. Age and sex matched controls were added in each experiment performed. 
All experiments were performed at least twice, with similar results. The animal 
procedures were performed according to protocols approved by the Istituto Clinico 
Humanitas and the Italian Institutional Animal Care and Use Committee. 
8.2 Human Samples 
Analysis of nine-unrelated patients with hypomorphic RAG defects whose clinical, 
immunological and molecular features were consistent with OS disease. Neonatal 
patient’s samples were collected with the informed consent of their parents, by their 
respective clinicians, accordingly to the statements of the Ethical Committee of each 
referring medical centre. Peripheral blood mononuclear cells (PBMC) from peripheral 
blood of four RAG patients were purified on Ficoll gradient (Lympholyte cell 
separation media, Cedarlane).   
8.2 Adoptive transfer experiments 
For T cell transfer in immunodeficient hosts, total CD4+ T cells derived from pooled 
MLNs of Rag2+/+ and Rag2R229Q mice were isolated with FACSAria cell sorter 
(purity>95%). 4x106 purified CD4+ T cells were injected into recipient Rag1-/- mice 
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[165]. Weight loss was monitored daily. ELISA on colonic supernatants and FACS 
analysis were performed at the sacrifice.  
 
For the colitis induction by T cell transfer, CD4+ T cells were isolated by pooled spleens 
and MLNs of 10-wk-old Rag2+/+ or Rag2R229Q mice using CD4-specific magnetic beads 
via negative selection according to the manufacturer’s instructions (Miltenyi Biotec). 
Enriched CD4 T cells were subsequently sorted into naive CD4+CD25−CD45RBhi and 
regulatory CD4+CD45RB−CD25hi populations (>98% purity) using a cell sorter 
(FACSAria; BD). For colitis induction, 4 × 105 WT CD4+CD25−CD45RBhi naive T 
cells were i.p. transferred into Rag1−/− mice alone or with 1.5x105 CD4+CD25hi T reg 
cells from Rag2+/+ or Rag2R229Q mice. Recipient mice were weighted twice a week and 
sacrificed at week four after the transfer, when IBD was diagnosed by severe weight 
loss, as described by [166].  
 
For Treg transfer, 5x105 CD25hi GITR+CD4+ Treg cells (purity >98%) were sorted from 
spleens of Rag2+/+ mice and injected into Rag2R229Q mice, as described by [167]. Mice 
were analysed after 4 weeks. FACS and gene expression analysis were performed on 
gut tissues. Histological analysis of the intestine was also performed.  
 
For B cell adoptive transfer, CD19+ B cells were enriched from pooled spleens, MLNs 
and PPs derived from WT CD45.1 donor mice with anti-CD19 magnetic beads 
(Miltenyi Biotec). Then, B220+IgM+IgA- B cells were isolated with FACSAria cell 
sorter (purity >98%) and immediately injected i.v. into Rag2R229Q mice (30x106 B cells), 
as described by [168]. B cell reconstitution was monitored and recipient mice were 
analysed after 4 weeks. Concentration of IgA was measured by ELISA twice a week. 
Histological and gene expression analysis were performed on gut tissue at the sacrifice.    
8.3 Antibiotic treatment and faecal transplantation  
For antibiotic treatment, Rag2+/+ and Rag2R229Q mice underwent four week-antibiotic 
treatment by oral gavage: Ampicillin (2.5 mg), Metronidazole (2.5 mg) and Vancomicin 
(1.25 mg) were administered in a solution in 200 µl/mouse, as described by [169]. 
Importantly, the antibiotic regimen resulted in about 90% reduction of total intestinal 
bacterial DNA, as measured by quantitative PCR. 
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Faecal transplantation experiments were performed as described by [170]. For faecal 
transplantation experiments, recipient Rag2+/+ and Rag2R229Q mice received long-term 
antibiotic treatment (30 days) to deplete the resident microbiota. Then, faecal pellets 
were collected from donor Rag2+/+ and Rag2R229Q mice, suspended in sterile PBS and 
homogenized. The faecal suspension obtained was introduced by gavage with the 
flexible plastic tube into the stomachs of each donors. The faecal suspension was given 
twice, one week apart. After the transplantation, recipient Rag2+/+ and Rag2R229Q mice 
colonized with the same intestinal microbiota were maintained in dedicated cages until 
the sacrifice. Recipient mice were sacrificed 3wk after the second microbiota transfer.    
8.4 IgA-coated bacteria 
Faecal pellets were homogenized and stained with anti-mouse IgA (mA-6E1, 
eBioscience). The bacteria were suspended with 4% of formalin overnight at 4°C and 
re-suspended in DAPI/PBS for FACS analysis (CANTO II, BD) using forward scatter 
(FSC) and side scatter (SCC) parameters in logarithmic mode. FlowJo software (9.6.6, 
Tree Star) was used for data analysis.   
8.5 ELISA assay 
For faecal immunoglobulin evaluation, faecal pellets were collected, weighed and 
suspended in 1 ml of PBS containing 0,1% sodium azide and protein inhibitor. Faecal 
IgA/IgM levels were measured by a mouse IgA/IgM ELISA quantification set (Bethyl 
Laboratories, Inc.), according to the manufacture’s instructors. Serum IgE was 
measured by specific ELISA (BD). Quantification of cytokines, such as IFNγ, TNFα, 
CCL17 and CCL22, was performed with mouse ELISA kit (R&D systems). Briefly, 
1cm of colonic tissue was incubated at 37°C for 48h, then supernatants were collected 
and cytokines determination was performed using ELISA kit. Human CCL17 and 
CCL22 were detected with human ELISA kit (R&D systems). 
8.6 LPS measurement 
Sera were collected from Rag2+/+ and Rag2R229Q mice in endotoxin-free conditions and 
stocked at -20. LPS concentration was determined by Limulus amebocyte lysate assay 
(Lonza) according to the manufacturing’s instructions. This method utilizes a 
preparation of Limulus Amebocyte lysate (LAL) and a synthetic color producing 
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substrate to detect endotoxin chromogenically. The lyophilized endotoxin (E. Coli 
0111:B4) was used for preparing standard solutions, ranging from 1 to 0.1 EU/ml.  
8.7 Quantification of adherent bacteria to mucosal and cutaneous epithelium 
One cm of skin biopsies or 1 cm-terminal ileum were collected from age–and sex-
matched mice using sterile condition and digested in lysis buffer (10 mM TRIS, 10 mM 
Tris, 100 mM NaCl, 10 mM EDTA, 0.5% SDS, and 0.4 mg/ml proteinase K). Total 
DNA was extracted with the isopropanol-ethanol method. The microbial load was 
determined with real time PCR (RT-PCR) (Syber Green) using 16s and 18s specific 
probes.   
8.8 LP and skin preparation 
Small intestines and colons were flushed to remove faecal contents, open longitudinally 
and cut into small pieces. To remove the epithelial layer, intestines were washed in 
HBSS buffer (0.5 M EDTA, 1 mM DTT, 15 mM Hepes, and 10% FCS) under agitation 
for 20 min at 37°C. Then, tissues were digested with Liberase TL (0.15 mg/ml, Roche, 
Sigma Aldrich, Taufkirchen, Germany) for 30 min at 37°C, washed and passed through 
100-µm cell strainers. The cell suspension obtained was stratified with 44/67% Percoll 
Gradient (GE Healthcare) and centrifuged at 600g for 20 min at RT. Lymphocyte phase 
was collected and analysed by flow cytometry with or without pre-stimulation with 
PMA (20ng/ml) and Ionomycin (1µg/ml). 
Skin tissue was digested with Liberase TL (0.45 mg/ml, Roche) for 1h at 37°C in 
agitation. Cells were washed and passed through 100-µm cell strainers. The resulting 
skin suspensions were further analysed by flow cytometry with or without pre-
stimulation with PMA (5ng/ml) and Ionomycin (1µg/ml).  
8.9 Lymph flow assessment using Evans blue dye 
Three µL of 1% Evans blue dye solution in PBS was injected into the back of 
anesthetized Rag2R229Q mice and controls using a Hamilton syringe. After 16h, all mice 
treated were sacrificed. Evans blue dye was extracted from the skin biopsies of the back 
by incubating them at 55°C for 5.5 hours in formamide (Fluka). The absorbance was 
measured with microplate reader at 620 nm. The dye concentration was calculated from 
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a standard curve of Evans blue dye in formamide and is represented as absolute amount 
of dye remained in the skin tissue.  
8.10 OT-I and OT-2 adoptive transfer 
Splenic CD8+ OT-I cells or CD4+ OT-II cells were sorted from donor mice (purity 
>98%). CD8+ OT-I cells or CD4+ OT-II cells (3*106) were adoptively transferred i.v. 
into Rag2+/+ and Rag2R229Q mice (CD45.1). The day after, ears were immunized. 
Briefly, both sides of each ear were gently stripped 10 times with Scotch Tape (3M), 
then 25µl of acetone was applied and evaporated. Next, 20 µl of cholera toxin (CT) or 
CT+ 50 µl of Ovalbumin (100 mg/ml OVA, cod. A5503, Sigma Aldrich) was applied 
with a small paintbrush on the ears of recipient mice. Rag2+/+ and Rag2R229Q mice were 
sacrificed after 7 days from topical immunization, as described by [171].  
8.11 DSS chronic treatment 
Chronic colitis was induced by adding dextran sulfate sodium (DSS, 2%) to drinking 
water ad libitum for 4 cycle. Control mice received water continuously thought all the 
experiment. At the end, mice were euthanized and skin tissues were collected for FACS 
and histological analysis.     
8.12 Co-culture DC-T cells  
Topical Immunization of ear skin of Rag2+/+ and Rag2R229Q mice was performed as 
described above. Briefly, CT plus OVA or CT alone as control was applied directly on 
ear skin. After 4 days, DCs from spleen and cervical LNs were sorted with FACSAria 
cell sorter (purity >98%) from OVA immunized- Rag2+/+ and Rag2R229Q mice and CT 
controls. OVA-loaded DCs were put in co-culture with CD4+ OT-II cells harvested 
from OT-II mice in 96-well-round bottom plates. A 1:1 DC:T cell ratio was used for the 
assay. Co-cultures were maintained for 6 days and T cell proliferation was evaluated by 
the incorporation of (3H)-thymidine.   
8.13 Topical and systemic LPS      
Rag2+/+ and Rag2R229Q mice, aged 8-10 weeks, were anesthetized and injected intra-
dermally into the back with 100µg of LPS (right side) and PBS (left side) using 
Hamilton syringe. After 24h, LPS-treated mice were sacrificed and skin tissues were 
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processed for histological analysis and quantitative RT-PCR analysis. For systemic LPS 
administration, Rag2+/+ and Rag2R229Q mice were injected i.p. with 100µg of LPS. 
Systemic LPS-treated mice were sacrificed 24h later. Skin tissues were used for 
histological scores and transcriptional analysis.  
8.14 OVA-intradermal injection  
Rag2+/+ and Rag2R229Q mice, 8-10 weeks old, were injected intra-dermally into the ear’s 
skin with 100 µg/ml OVA-Alexa FluorTM (Thermo Fisher Scientific) with Hamilton 
syringe. After 6h, cervical LNs and ear tissues were collected and digested with 
Liberase TL (0.45 mg/ml, Roche, Sigma Aldrich, Taufkirchen, Germany) for 30 min at 
37°C. The analysis of OVA-loaded CD11C+ DCs from ears and cervical LNs was 
performed by FACS. Mice injected intra-dermically with PBS-/- were used as negative 
control.   
8.15 Flow cytometry  
Cell suspensions obtained from intestines, spleens, MLNs, DLNs and skins were pre-
incubated with FcγR-specific blocking antibodies (eBioscience) and stained with the 
following antibodies: TCR-β (clone H57.597,	eBioscience), TCR-γδ (clone UC7-13D5, 
eBioscience), CD3 (clone 17A2,	eBioscience), CD45 (clone 30-F11, eBioscience), CD4 
(clone RM4-5, eBioscience), CD8a (clone 53-6.7, eBioscience), CD62L (clone Mel14,	
eBioscience), CD44 (clone IM7, BD), CD45R (B220; clone RA3-6B2,	 eBioscience), 
CD357 (GITR; clone DTA-1, eBioscience), CCR9 (clone eBio CW-1.2,	eBioscience), 
α4β7 (clone DATK32,	BioLegend), Foxp3 (clone MF23,	eBioscience), IgA (clone mA-
6E1, eBioscience), IgM (clone II/41,	eBioscience), CD25 (clone PC61.5,	eBioscience), 
CD103 (clone 2E7, eBioscience), CD45RB (clone C363-16A, BioLegend), CD11C 
(clone N418, eBioscience), MHCII (M5/114.15.2, eBioscience). Exclusion of dead cells 
was performed with Aqua Cell Stain kit (Invitrogen). For intracellular staining, cells 
were stimulated for 4h with PMA and Ionomycin. Golgi stop (1000x, BD) was added 
during the last 3h of stimulation. Cell fixation and permeabilization was performed 
using the intracellular fixation and permeabilization buffer kit (eBioscience). 
Intracellular staining was performed using the following antibodies: IL-17A (clone 
eBio17B7,	eBioscience) and IFNγ (clone XMG1.2,	eBioscience). For human samples, 
cells were stained with the following antibodies: CD4 (clone RPA-T4, eBioscience), 
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CD8 (clone RPA-T8), CD45RA (clone HI100, BD), CD45RO (clone UCHL1, 
BioLegend), CCR9 (clone BL/CCR9, BioLegend), CLA (clone HECA-452, 
BioLegend). FACS data were acquired with FACS CANTO II and analysed with 
FlowJo software (9.6.6, Tree Star).  
8.16 Quantitative real time RT-PCR  
Total cellular RNA was extracted from 1 cm of mouse ileal/colonic tissues or back skin.  
Tissues from intestines, skin, kidney, liver and lung were homogenised in PureZOL 
reagent (Bio-Rad Laboratories) using TissueLyzer II (QIAGEN). Then, RNA was 
extracted using RNeasy Lipid Tissue kit (QIAGEN).  A total of 1 µg of RNA was used 
to synthetize cDNA using the High-Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems). The expression of mouse cytokines and chemokines was investigated by 
SYBR-green RT-PCR using the CFX384 system (Bio-Rad Laboratories). For sorted 
cells, total RNA was extracted by RNeasy Plus Micro kit (QIAGEN), retro-transcribed 
and pre-amplified using TaqMan PreAmp MasterMix (Applied Biosystems). 
Quantitative RT-PCR was run on ViiA7 system (Thermo Fisher Scientific) with 
TaqMan probes. The housekeeping gene β-actin (Actb) ribosomal RNA was used as 
control. List of primers used in the study (Table 2).  
8.17 Histology and immunohistochemistry 
Mouse tissue samples were formalin-fixed and paraffin-embedded. Sections (1,5 µm) 
were used for routine hematoxylin and eosin (H&E) staining to check for basic 
histopathological changes. Moreover, sections were de-waxed, rehydrated, endogenous 
peroxidase activity blocked by 0.1% H2O2, nonspecific background reduced with 
Rodent Block (Biocare Medical) before microwaves or thermostatic bath treatment and 
incubated with primary antibodies for 1h at RT. The following primary antibodies were 
used: rabbit anti-CD3 (1:100; ThermoFisher Scientific; EDTA buffer pH 8.0), rat anti-
FoxP3 (1:100; eBioscience; EDTA buffer pH 8.0) and goat anti-CD31 (1: 1000; R&D 
system; DIVA Decloaker 1x Biocare Medical). Depending on the primary antibodies 
and tissue used, sections were incubated with Goat-on-Mouse HRP-Polymer (Biocare 
Medical),	MACH 1™ Universal HRP Polymer Kit (Biocare Medical), Rat-on-Mouse 
HRP-Polymer (Biocare Medical) or Real EnVision Rabbit-HRP (Dako), and reactions 
were developed in Biocare's Betazoid DAB and nuclei counterstained with Hematoxilin 
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(Dako). Digital images were acquired by Olympus XC50 camera mounted on a BX51 
microscope (Olympus) or by Olympus DP70 camera mounted on a Bx60 microscope 
(Olympus), with CellF Imaging software (Soft Imaging System GmbH).  
Quantification of CD3+ cells and area of liver, lung, and kidney sections was performed 
by Aperio ScanScope CS Slide Scanner (Aperio Technologies) and the absolute number 
of CD3+ cells was expressed as the number of CD3+ cells/mm2.  
8.18 Histological score 
Arbitrary gut (SI and colon) and skin histological score was calculated in double blind 
study by a pathologist. Scoring from 0 to 3 (where 0 is normal condition and 3 is severe 
structural changes) was adopted for evaluating different manifestations in each tissue. 
For gut analysis, a combined score was used: grade of inflammation, the structural 
changes of the glands, and the goblet cell depletion. For skin analysis, abnormalities of 
keratinocytes, increased immune cells in the dermis, alterations of the epidermis and 
presence of cutaneous abscesses were evaluated. Specifically, for DSS treatment, the 
number of CD3+-aggregates was also analysed as additional parameter in the score.  
8.19 Morphometric analysis 
Villous height and crypt depth were randomly measured for 16 well-oriented villi of 
distal ileum per mouse and data were analyzed using commercial image analysis 
software (ImageJ; National Institutes of Health). CD31 morphometric analysis was 
performed using Olympus Slide Scanner VS120-L100 to acquire digital images and 
Image-pro software to evaluate coverage, vessels number and size. 
8.20 Microbiota analysis 
For the evaluation of intestinal microbiota, weaned Rag2R229Q and Rag2+/+ littermates 
were co-housed in the same cages until analysis. The bacterial microbiota of 20 faecal 
samples from 10 Rag2+/+ and 10 Rag2R229Q mice was explored by sequencing the V5-
V6 hypervariable regions of 16S rDNA gene by using the Illumina MiSeq platform. The 
obtained 250 × 2 paired-end reads were taxonomically profiled by applying the BioMaS 
pipeline [172]. Paired-end reads of each sample were merged into consensus sequences 
using Flash (Adobe) and then dereplicated by Usearch (drive5). The unmerged reads 
were trimmed of low-quality regions (Phred score cutoff of 25), and paired ends 
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containing reads shorter than 50 nucleotides were removed. Both the merged sequences 
and the unmerged reads were mapped against the RDP II database (release 10.32) by 
using Bowtie 2. The mapping data were filtered according to query coverage (≥70%) 
and similarity percentage (≥97%) and were stored in a file format suitable for the 
taxonomic assignment steps. Finally, the Tango tool processed the similarity analysis 
data to assign the sequences to a taxonomic clade in the NCBI taxonomy. Statistically 
significant differences of the bacterial population in Rag+/+ and Rag2R229Q mice were 
determined at family, genus, and species levels by using the R/Bioconductor DESeq 
package. 
8.2.1 Cutaneous microbiota analysis 
For the evaluation of cutaneous microbiota, weaned Rag2+/+ and Rag2R229Q littermates 
were maintained in separated cages until analysis. Approximately 1-cm of cutaneous 
tissue was collected from the back of 10 Rag2+/+ and 10 Rag2R229Q mice. Cutaneous 
tissues were weight and digested in lysis buffer (10 mM Tris, 100 mM NaCl, 10 mM 
EDTA, 0.5% SDS, and 0.4 mg/ml proteinase K). Total DNA was extracted with the 
isopropanol-ethanol method. The presence of bacterial DNA in all samples was verified 
by real-time PCR using specific primers for microbial 16s rRNA gene. Subsequently, 
the bacterial community structure of the DNA samples isolated from skin was profiled 
through by sequencing the V3 variable region (Illumina MiSeq technology) as described 
in [173]. The resulting sequence reads were managed by means of the pipeline 
Quantitative Insights Into Microbial Ecology (QIIME) version 1.7.0 with the 
GreenGenes database (version 13.5). To identify the specific bacterial taxa 
distinguishing the skin microbiota of Rag2+/+ from Rag2R229Q mice, we used the linear 
discriminant analysis effect size (LEfSe) method.	
8.22 Statistical analysis 
Results were analyzed using the nonparametric Mann-Whitney test, Student’s unpaired t 
test, and two-way ANOVA with Bonferroni post-test analysis. Results are presented as 
mean ± SEM. Values of P < 0.05 were considered statistically significant. 
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Table 2: List of primers used in the study 
 
SyberGreen Primers 
  Actb for CTAAGGCCAACCGTGAAAAG 
Actb rev ACCAGAGGCATACAGGGACA 
  IL-17A for TCCAGAAGGCCCTCAGACTA 
IL-17A rev TGAGCTTCCCAGATCACAGA 
  IFNγ for TCAAGTGGCATAGATGTGGAAGAA 
IFNγ rev TGGCTCTGCAGGATTTTCATG 
  IL-22 for TGACGACCAGAACATCCAGA 
IL-22 rev AATCGCCTTGATCTCTCCAC 
  IL-10 for GGTTGCCAAGCCTTATCGGA 
IL-10 rev ACCTGCTCCACTGCCTTGCT 
  IL-5 For ATCCAGGAACTGCCTCGTC 
IL-5 Rev ATCCAGGAACTGCCTCGTC 
  IL-13 For CCTCTGACCCTTAAGGAGCTTAT 
IL-13 Rev CGTTGCACAGGGGAGTCT 
  IL-33 For TCCTTGCTTGGCAGT 
IL-33 Rev TGCTCAATGTGTCAA 
  IL-6 for GTAGCTATGGTACTCCAGAAGAC 
IL-6 rev ACGATGATGCACTTGCAGAA 
  TNFα for GACGTGGAACTGGCAGAAGAG 
TNFα rev TTGGTGGTTTGTGAGTGTGAG 
  Reg3γ for TTCCTGTCCTCCATGATCAAAA 
Reg3γ rev CATCCACCTCTGTTGGGTTCA 
  IL-1β for GCCCATCCTCTGTGACTCAT 
IL-1β rev AGGCCACAGGTATTTTGTCG 
  CCL2 for CTGGATCGGAACCAAATGAG 
CCL2 rev AAGGCATCACAGTCCGAGTC 
  CCL20 for AACTGGGTGAAAAGGGCTGT 
CCL20 rev GTCCAATTCCATCCCAAAAA 
  CXCL10 for GCTGCCGTCATTTTCTGC 
CXCL10 rev TCTCACTGGCCCGTCATC 
  CXCL9 for CTTTTCCTCTTGGGCATCAT 
CXCL9 rev GCATCGTGCATTCCTTATCA 
  CCL5 for GTGCCCACGTCAAGGGTAT 
CCL5 rev CCCACTTCTTCTCTCCTGGGTTG 
  CCL25 for GAGTGCCACCCTAGGTCATC 
CCL25 rev CCAGCTGGTGCTTACTCTGA 
  16s for GTGSTGCAYGGYTGTCGTCA 
16s rev ACGTCRTCCMCACCTTCCTC 
  18s for CTCAACACGGGAAACCTCCTCAC 
18s rev CGCTCCACCAACTAAGAAGG 
  IL-4 for CATCGGCATTTTGAACGAG 
IL-4 rev CGAGCTCACTCTCTGTGGTG 
  IL-23p19 for AGCCAGTTCTGCTTGCAAAGG 
IL-23p19 rev GGAGGTTGTGAAGTTGCTCCATG 
  TGFβ for TGGAGCAACATGTGGAACTC 
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TGFβ rev GTCAGCAGCCGGTTACCA 
  IL-12p35 for CTATCTGAGCTCCGCCTGAAAG 
IL-12p35 rev GGCCAAGACCACCTGACTCTTA 
  Jam-a for AGAACAAAGAAAGGGACTGCAC 
Jam-a rev ACCAGGAACGACGAGGTCT 
  Occludin for ATTCCGGCCGCCAAGGTTCG 
Occludin rev GCTGGCTGAGAGAGCATCGGC 
  Claudin-1 for ACTGCCCTGCCCCAGTGGAA 
Claudin-1 rev TCAGCCCCAGCAGGATGCCA 
  Cramp For AAGGAGACTGTATGTGGCAAGGCA 
Cramp Rev TTTCTTGAACCGAAAGGGCTGTGC 
  mBD-3 For GTCAGATTGGCAGTTGTGGA 
mBD-3 Rev GCTAGGGAGCACTTGTTTGC 
  VEGF-A For CAGGGCTTCATCGTTACAG 
VEGF-A Rev CATCTTCAAGCCGTCCTGT 
  TLR-2 For AGCATCCTCTGAGATTTGA 
TLR-2 Rev GGGGCTTCACTTCTCTGCTT 
  TLR-3 For TCCCCCAAAGGAGTACATT 
TLR-3 Rev GATACAGGGATTGCACCCA 
  TLR-4 For GGACTCTGATCATGGCACTG 
TLR-4 Rev CTGATCCATGCATTGGTAGGT 
  TLR-5 For CTGGAGCCGAGTGAGGTC 
TLR-5 Rev CGGCAAGCATTGTTCTCC 
  TLR-9 For GAGAATCCTCCATCTCCCAAC 
TLR-9 Rev CCAGAGTCTCAGCCAGCAC 
  TSLP For CAGCTTCGTCTCCTGA 
TSLP Rev AAATGTTTTGTCGGGGAGTG 
  CK5 For CATTCTCAGCCGTGGTACG 
CK5 Rev CAGAGCTGAGGAACATGCAG 
  CK6 For GTCCAGGACCTTGTTCTGCT 
CK6 Rev ATCCAGCGGGTCAGGACT 
  CCL22 For CTGATGCAGGTCCTATGGT 
CCL22 Rev GGAGTAGCTTCTTCACCCAG 
  CCL17 For TGCTTCTGGGGACTTTTCTG 
CCL17 Rev GAATGGCCCCTTTGAAGTAA 
 
 
 
 
 
 
 
 
 
 
 
TaqMan Probes 
Actb  Mm00607939_s1  
  Rorc  Mm01261022_m1  
  Tbx21  Mm00450960_m1 
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9. RESULTS 
	
9.1 Study of the intestinal pathology in Rag2R229Q mice 
9.1.1 Intestinal inflammation affects Rag2R229Q mice 
 
Analysis of intestinal disease in Rag2R229Q mice revealed marked signs of intestinal 
inflammation but different degree of spontaneous colitis, wasting diarrhoea, and rectal 
prolapse. Approximately 5% of mutant mouse colony manifested rectal prolapse by 24 
weeks of age. Histologically, colonic inflammation in Rag2R229Q mice was characterized 
by epithelial hyperplasia, crypt elongation, and a large inflammatory infiltrate along the 
LP, with occasional crypt abscesses (Figure 19A). Several morphological alterations 
affected also the small intestine, including increased mucosal thickness and histological 
score with lower villus/crypt ratio (Figure 19B-C). Occasionally, large lymphoid 
aggregates containing CD3+ T cells were observed in the peri-intestinal fat of Rag2R229Q 
mice (data not shown). Moreover, immunophenotypic analysis demonstrated that 
intestinal LP infiltrates consisted of T cells, particularly of CD4+, with very few CD8+ T 
cells (Figure 19D). Furthermore, absolute counts of infiltrating T cells were three-six 
fold higher in mutant mice compared to controls, in sharp contrast with the overall 
lymphoid depletion observed in the other lymphoid organs, including thymus, spleen 
and lymph nodes (data not shown). The proportion of pro-inflammatory Th1/Th17 cells 
was enriched in the intestine of Rag2R229Q mice compared to controls. Moreover, the IL-
17/IFNγ double-producing population, frequently found in the intestine of patients with 
Crohn disease, was abundant in the mutant gut [174] (Figure 19E-F). To deeply 
characterize the intestinal inflammatory environment in Rag2R229Q mice, we analysed 
the expression of several cytokines. Expression level of IFNγ, IL-17, IL-6, IL-2, IL-1β, 
IL-22 and TNFα were significantly up-regulated in both ileum and colonic tissues of 
Rag2R229Q mice. On the contrary, IL-10 and IL-12p35 were significantly down-
regulated, whereas IL-4, TGFβ and IL-23p19 did not change significantly (Figure 
19G). Collectively, these results indicated that pathogenic Th1\Th17 cells mediate 
intestinal inflammation in Rag2R229Q mice.   
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Figure 19: Characterization of intestinal inflammation in Rag2R229Q mice. 
Representative colonic (A) and SI (B) sections from Rag2R229Q mice and controls 
stained with H&E and CD3 immunostaining. Graphs show the inflammatory scores. 
Asterisks indicate the area of infiltration. (C) Villus/crypt ratio and representative 
images of SI villi from Rag2R229Q mice and controls. (D) Representative FACS dot plot 
of CD4/CD8 infiltrating intestinal LP. (E) Representative FACS dot plots, absolute 
counts and frequencies of Th17, Th1 and Th1/Th17 populations from SI and colonic LP. 
(G) Transcriptional expression of cytokines from SI and colonic tissues. RNA contents 
are shown as arbitrary units (A.U.). 8-12 week-old mice of indicated genotypes were 
analysed.  Mann Whitney test; values are mean ± SEM. *, P < 0.05; **, P < 0.01; ***, 
P < 0.001. 
9.1.2 Rag2R229Q CD4+ T cells have enhanced gut tropism and cause colitis 
The migration to the intestinal mucosa requires the expression of specific gut homing 
receptors on T cells, the integrin α4β7 and the chemokine receptor CCR9 [175]. 
Consistently with the intestinal inflammation, we found increased frequency of CCR9 
and a4b7-expressing CD4+ T cells in the MLNs of mutant mice compared to controls 
(Figure 20A). Interestingly, the proportion of CCR9 and a4b7-expressing splenic T 
cells was also augmented in Rag2R229Q mice, indicating the peripheral dissemination of 
T cells activated within the intestine in mutant mice. To directly investigate whether 
CD4+ T cells could be sufficient to induce gut inflammation, we transferred total CD4+ 
T cells from Rag2+/+ and Rag2R229Q MLNs into Rag1-/- immunodeficient hosts. All mice 
transferred with Rag2R229Q CD4+ T cells showed signs of colitis after 10 weeks. In 
particular, greater weight loss, colon shortening and high inflammatory score were 
detected in Rag1-/- receiving mutant CD4+ T cells compared to mice receiving wild-type 
CD4+ T cells (Figure 20B-C). Of note, MLNs and spleens were enlarged in recipient 
mice receiving CD4+ T Rag2R229Q cells (Figure 20D). Remarkably, in the MLNs of 
Rag2R229Q-chimeric Rag1-/- mice, we detected a prominent expansion of activated T 
cells (CD44hi, CD45RBlow, CD25+) with Th1/Th17 skewing, resembling the 
inflammatory state typical of Rag2R229Q condition (Figure 20E). Interestingly, the 
analysis of the cytokine profile of chimeric Rag1-/- mice revealed two to five fold 
increased level of IL-2, IFNγ, IL-17 and TNFα in the colonic supernatants of Rag2R229Q-
chimeric Rag1-/- mice compared to Rag2+/+-chimeric Rag1-/- controls. On the contrary, 
the expression level of IL-4 and IL-10 were markedly reduced (Figure 20F). 
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Collectively, these results suggested that mutant CD4+ T cells are sufficient to transfer 
the disease into immunodeficient host.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
84 
	
Figure 20: Rag2R229Q CD4+ T cells transfer the disease into Rag1-/- mice.  A) FACS 
dot plots and frequencies of CCR9+ and α4β7-expressing CD4+ T cells derived from 
MLNs and spleen of Rag2R229Q mice and wild-type mice. B) Body weight loss (%) of 
control Rag1-/- mice and Rag1-/- mice receiving Rag2+/+and Rag2R229Q total CD4+ T 
cells. C) Inflammatory score of colons at sacrifice. Representative images of 
macroscopic observation in colons and spleens. (D) Total cellularity of MLNs and 
spleens derived from Rag1-/- mice receiving Rag2+/+and Rag2R229Q total CD4+ T cells. 
E) Representative FACS dot plots of immune-phenotype of total CD4+ T cells isolated 
from MLNs. (F) Cytokine profile of cultured colonic tissues. RNA contents are shown as 
arbitrary units (A.U.). 8-12 week-old mice of indicated genotypes were analysed.  Mann 
Whitney test; values are mean ± SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001. 
     
9.1.3 Treg impairment contributes to intestinal inflammation in Rag2R229Q mice 
In the gastrointestinal tract, regulatory T cells play a crucial role in maintaining immune 
homeostasis and promoting tolerance against intestinal antigens and commensal bacteria 
[176]. Interestingly, we detected higher absolute count and frequency of Foxp3+ GITR+ 
Treg cells in the mutant SI and colonic LP compared to controls. However, Treg cells 
were augmented only in frequency in the MLNs, underlying that Treg expansion 
represented a unique feature of the LP compartment (Figure 21A).  
To understand whether mutant Tregs were able to suppress intestinal inflammation in 
vivo, we employed the experimental model of colitis induced by adoptive transfer of 
naïve CD45RBhi cells in immunodeficient hosts. In particular, we transferred wild-type 
CD4+CD45RBhi into the Rag1-/- mice, in presence or absence of CD4+CD25hi Tregs 
derived from Rag2+/+ and Rag2R229Q mice. Recipient mice were sacrificed after 4 weeks. 
As expected, mice co-transferred with naïve T cells and wild-type Tregs showed 
reduced signs of colitis (Figure 22A). On the contrary, mutant Tregs failed to control 
efficiently intestinal inflammation in Rag1-/- mice. These findings indicated that Treg 
function was compromised in Rag2R229Q mice. To directly assess whether the gut 
inflammation could be a consequence of Treg impairment, we adoptively transferred 
wild-type Tregs into Rag2R229Q mice. Specifically, recipient mice were injected i.v. with 
CD4+CD25hiGITR+ cells derived from wild-type 45.1 and were followed for 4 weeks 
(Figure 22B). Remarkably, at the sacrifice we observed amelioration of intestinal 
inflammation, characterized by reduced lymphocytic infiltration as well as decreased 
frequency of mucosal Th1/Th17 cells (Figure 22C-E). Consistently, lower expression 
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of IL-17 and IFNγ was detected in the intestinal tissue of Treg transferred-Rag2R229Q 
mice (Figure 22F). These data indicated that transfer of wild-type Tregs could attenuate 
gut inflammation by reducing Th1/Th17 immune responses and confirmed that mutant 
Tregs failed to control colitis. 
 
 
Figure 21: Treg expansion in the gut of Rag2R229Q mice. A) Representative FACS dot 
plots, frequencies and absolute counts of Foxp3+ GITR+ Treg cells in the SI, colon and 
MLNs. 8-12 week-old mice of indicated genotypes were analysed. Mann Whitney test; 
values are mean ± SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001. 
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Figure 22: Treg impairment in Rag2R229Q mice. A) Colitis score and representative 
colonic sections from Rag1-/- transferred with CD45RBhi alone or with Rag2+/+ and 
Rag2R229Q Tregs. Asterisks indicate the area of infiltration. B) Wild-type Tregs were 
adoptively transferred into Rag2R229Q mice. C) Lymphocytes counts in the SI and colon. 
D) Representative colonic sections stained with H&E and colitis score in Treg cell 
transfer group and controls. Asterisk indicates the area of infiltration. E) 
Representative FACS dot plots and frequencies of LP Th17 and Th1 from SI and colon. 
F) Transcriptional expression of several cytokines. RNA contents are shown as 
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arbitrary units (A.U.). 8-12 week-old mice of indicated genotypes were analysed. Mann 
Whitney test; values are mean ± SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001. 
    
9.1.4 B cells are required to maintain intestinal homeostasis and avoid bacterial 
translocation in Rag2R229Q mice 
Mucosal IgA regulate the function and the composition of the intestinal microbiota to 
maintain mutualism between the host and the commensal bacteria [177]. In contrast to T 
cells, B cells were poorly present in the intestine of Rag2R229Q mice, as shown by the 
lack of Peyer’s Patches and the nearly absence of B220+ cells infiltrating the intestinal 
LP (Figure 23A). In agreement, we found reduced level of faecal IgA and IgM, 
suggesting a general B cell deficiency at the mucosal interfaces (Figure 23B). As 
expected, a marked reduction of IgA-coated bacteria was detected in the colon of 
mutant mice (Figure 23C). A recent study demonstrated the lack of IgA correlates with 
higher level of serum LPS [178]. In this regard, we found augmented adherent bacteria 
to the ileum mucosa, measured as a ratio between prokaryotic to eukaryotic DNA, and 
increased concentration of serum LPS (Figure 23G-H). These findings indicated that B 
cell deficiency associates to enhanced translocation of bacterial products from the 
intestinal lumen to the periphery. To better unravel the contribution of B cells in the 
intestinal disease pathogenesis, we transferred wild-type-B cells in mutant mice. Indeed, 
wild-type- CD19+IgM+IgD+ B cells from pooled spleens, lymph nodes and Peyer’s 
Patches were isolated and injected into Rag2R229Q mice (Figure 23D). IgA-producing 
plasma cells were generated rapidly in B cell-transferred group (Figure 23E). In 
response to elevated IgA levels, we detected a normalization of Reg3γ in the ileum 
tissue of B cell-transferred mutant mice, normally up-regulated in the intestinal tissue 
(Figure 23F). Interestingly, we found reduced mucosal adherent bacteria and lower 
LPS translocation in B cell transfer mutant group (Figure 23G-H). Moreover, reduced 
stimulation of intestinal mucosa attenuated the colonic inflammation in mutant mice 
(Figure 23I). Overall these results indicated that B cell compartment is essential but not 
sufficient to maintain intestinal homeostasis.  
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Figure 23: Mucosal B cell deficiency in Rag2R229Q mice. A) Representative FACS dot 
plots of B cells-infiltrating intestinal LP of Rag2R229Q mice and controls. B) ELISA of 
faecal IgA and IgM. C) Representative FACS dot plots and frequencies of IgA-coated 
bacteria derived from faeces of Rag2R229Q and controls. D) Experimental procedure: 
wild-type-30*106 CD19+B220+IgM+ B cells were transferred into Rag2R229Q mice. Flow 
cytometry shows the percentage of B cells in the intestine of Rag2R229Q mice after B cell 
transfer. E) Time course of faecal IgA levels after B cell transfer. F) Transcriptional 
expression of Reg3γ from SI and colonic tissues. G) Prokaryotic/eukaryotic ratio. H) 
Serum concentration of LPS. I) Representative SI and colon sections of B cell-
transferred Rag2R229Q and controls stained with H&E. Graphs represent the 
inflammatory score. Asterisks indicate the area of infiltration. 8-12 week-old mice of 
indicated genotypes were analysed. Mann Whitney test; values are mean ± SEM. *, P < 
0.05; **, P < 0.01; ***, P < 0.001. 
   
9.1.5 Rag2R229Q mice show altered microbial composition 
Diversified IgAs contribute to maintenance of heterogeneous and balanced intestinal 
microbiota [104]. To explore whether Rag2R229Q condition could be characterized by 
microbial alterations, we evaluated the microbiota composition in mutants and their 
cohoused wild-type littermates, by 16s sequencing of bacterial DNA extracted from 
caecal contents. By this approach, we investigated the relative abundance and the 
diversity of bacterial taxa in the microbiota profiles of Rag2R229Q and Rag2+/+ mice.       
Importantly, no substantial differences in the relative abundance of the dominant 
intestinal taxa were found (Actinobacteria, Bacteriodetes, Firmicutes and 
Proteobacteria) (data not shown). However, considerably less bacterial diversity at the 
family and genus levels was detected in Rag2R229Q mice versus controls, as determined 
by the Shannon and the Chao1 index of α-diversity (Figure 24A). 
Furthermore, hierarchical clustering based on the relative abundance of bacteria 
indicated that Rag2R229Q and Rag2+/+ mice formed clusters according to the genotypes 
(Figure 24B). Moreover, we performed a partial least squares (PLS1) regression 
analysis to identify the bacterial taxa that better represented the difference between 
Rag2R229Q mice and controls. The analysis took into consideration the overall 
composition of the intestinal microbiota, using genotypes as categorical responses and 
the relative abundance of bacterial genera as continuous predictors. PLS1 analysis 
confirmed the reduced bacterial richness that characterized Rag2R229Q mice. 
Furthermore, the analysis revealed an important enrichment of several genera of the 
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phylum Proteobacteria, previously associated to IBD [179], in the mutant intestinal 
microbiota (Figure 24C). Overall these findings revealed that mutant microbiota exhibit 
less microbial diversity and high abundance of Proteobacteria  
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Figure 24: Altered microbiota composition in Rag2R229Q mice. A) Box and whisker 
plots of the Shannon diversity index at the bacterial genera and family level in Rag2+/+ 
and Rag2R229Q mice. B) Heatmap of the relative abundance of each bacterial family 
from sequencing of faecal samples of Rag2+/+ mice and Rag2R229Q mice. C) Correlation 
between mouse genotype and bacterial genera in faecal samples of Rag2+/+ mice and 
Rag2R229Q mice. X-and Y loading plots (factors 1 and 2) were obtained by partial least 
squares performed by using the genotype as categorical response and the relative 
abundance of bacterial genera as continuous predictors. Taxa belonging to the phylum 
Proteobacteria was showed with red circle. 8-12 week-old mice of indicated genotypes 
were analysed. (A) Mann Whitney test; *, P < 0.05; **, P < 0.01. 
  
9.1.6 Long-term antibiotic treatment dampens intestinal inflammation in Rag2R229Q mice   
To directly assess the role of commensal bacteria in the pathogenesis of gut 
inflammation, we depleted intestinal microbiota of Rag2R229Q mice and controls, using a 
broad spectrum of antibiotics containing Ampicillin, Vancomycin and Metronidazole, 
given daily by oral gavage for four weeks. In antibiotic (ABX)-treated mutant mice, we 
found attenuated intestinal inflammation, characterized by a reduction of lymphocytic 
infiltrate as well as mucosal Th1/Th17 populations (Figure 25A-C). The proportion of 
these populations was low and unaffected in ABX Rag2+/+ mice.	Interestingly, intestinal 
expression level of several inflammatory chemokines, including cxcl9, cxcl10, ccl20, 
ccl2 and ccl5 resulted normalized upon ABX treatment in Rag2R229Q mice. Likewise, 
transcript level of ccl25, the chemokine supporting the recruitment of CCR9-expressing 
T cells to the small intestine [180], decreased to wild-type level in treated mutants 
(Figure 25D). All these results indicated that reduced bacterial load had a beneficial 
effect on mucosal inflammation.   
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Figure 25: Long-term antibiotics attenuate intestinal inflammation in Rag2R229Q 
mice. (A) Representative SI and colonic section from ABX treated- Rag2R229Q mice and 
controls stained with H&E and CD3 immunostaining. Graphs show the inflammatory 
scores after ABX treatment. Asterisks indicate the area of infiltration. (B) Cell counts of 
lymphocytes infiltrating SI and colonic LP. (C) Representative FACS dot plots, absolute 
counts and frequencies of Th1, Th17 and Th1/Th17 populations from SI and colon of 
ABX treated- Rag2R229Q mice and controls. (D) Expression level of many cytokines in 
intestinal tissue. 8-12 week-old mice of indicated genotypes were analysed. Mann 
Whitney test; values are mean ± SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001.  
  
9.1.7 Absence of TLR microbial recognition do not reduce the intestinal inflammation in 
Rag2R229Q mice 
To specifically investigate the role of MyD88-dependent microbial recognition in the 
intestinal pathogenesis, we generated Rag2R229Q mice carrying a complete deficiency in 
MyD88, the adaptor molecule common to most TLRs. Accumulating evidence 
demonstrated that Myd88 is essential for the induction of inflammatory cytokines, 
modulating both innate and adaptive immune responses [181]. Lymphocyte 
composition was not altered in Myd88-/- mice compared to Rag2+/+ mice. Importantly,    
like mutant mice, Rag2R229Q x Myd88-/- mice showed intestinal disease as well as 
lymphocytic infiltration in the intestinal LP (Figure 26A-B). Remarkably, the lack of 
MyD88 affected Th1 but not Th17 T cell skewing, suggesting that Th17 generation 
might be independent by TLR-Myd88 mediated pathways (Figure 26C). Consistently, 
the expression of the transcription factor Tbet was lower on intestinal CD4+ T cells in 
Rag2R229Q x Myd88-/- compared to Rag2R229Q mice (Figure 26D). These results indicated 
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that deficiency in the adaptor molecule MyD88 did not protect Rag2R229Q mice from 
intestinal inflammation.  
 
 
Figure 26: Myd88 deficiency affects only Th1 population in Rag2R229Q mice. A) 
Representative SI and colonic section from Rag2R229Q and Rag2R229Q x Myd88 -/- mice. 
Graphs represent the inflammatory scores. Asterisks indicate area of infiltration.  B) 
Cell counts of lymphocytes from SI and colon. C) Representative FACS dot plots and 
frequencies of Th17, Th1 and Th1/Th17 cells from the intestine of Rag2R229Q and 
Rag2R229Q x Myd88 -/- mice. D) mRNA expression of Tbet and RorγT on sorted CD4+ 
cells from SI and colon. 8-12 week-old mice of indicated genotypes were analysed. 
Mann Whitney test; values are mean ± SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001. 
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9.1.8 Long-term antibiotics treatment ameliorates systemic autoimmunity in Rag2R229Q 
mice 
To explore whether the effects of antibiotic treatment could extend beyond the 
gastrointestinal tract, we looked at the peripheral immune cell compartment. We 
observed reduced frequency of splenic Th1/Th17 and CCR9-expressing T cells in ABX-
treated mutant mice, demonstrating a role for microbial signals in the maintenance of 
peripheral activated T cells (Figure 27A-B). The proportion of these populations was 
unaffected in ABX-treated Rag2+/+mice. Interestingly, splenic GITR+ T cells were also 
reduced in ABX-treated mutant mice, indicating that most Treg cells were induced by 
commensal bacteria in Rag2R229Q mice (Figure 27C). Moreover, ABX-treated mutant 
mice showed lower serum level of IFNγ and TNFα compared to controls (Figure 27D). 
Previous findings revealed extensive lymphocytic infiltration in target organs, including 
skin, kidney, liver and lung, which contribute to the systemic autoimmunity of 
Rag2R229Q mice [65]. To assess whether long-term antibiotics attenuated the disease, we 
analysed tissue T cell infiltration. Remarkably, a significant reduction of CD3+ T cells 
infiltrating target organs was observed in ABX-treated mutant mice (Figure 27E). 
Consistently, we observed lower tissue expression of recruiting chemokines (cxcl10 and 
ccl2) (Figure 27F). On the contrary, skin infiltration was not affected by ABX 
treatment, suggesting that additional independent pathogenic mechanisms contribute to 
determine cutaneous inflammation in mutant mice (data not shown). Importantly, 
reducing bacterial load normalized the serum IgE levels, the clinical hallmark of OS 
disease.  A similar trend was observed for IgA and IgG, but not for IgM (Figure 27G).  
Collectively, these results indicated that reducing bacterial load attenuates systemic 
inflammation in Rag2R229Q mice.    
Next, to directly assess the pathogenicity of mutant intestinal microbiota independently 
of the host susceptibility, we performed experiments of faecal transplant by transferring 
mutant microbiota in wild-type recipients. Specifically, recipient mice were previously 
treated with long-term antibiotic treatment to deplete the resident microbiota. Then, 
faecal pellets were inoculated into recipient mice by oral gavage. Interestingly, re-
colonization of wild-type mice with Rag2R229Q faeces favoured the development of 
mucosal and splenic Th1/Th17 cells (Figure 28A). On the contrary, Rag2R229Q mice 
colonized with wild-type microbiota attenuated significantly the Th1/Th17 profile both 
in the intestinal and systemic compartment. Interestingly, Rag2R229Q mice colonized 
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with Rag2R229Q microbiota further increased the intestinal and systemic inflammation 
(Figure 28A). Overall these data suggested that intestinal microbiota of Rag2R229Q mice 
may be responsible for inflammatory exacerbation and shape both mucosal and 
systemic T cell responses towards Th1/Th17 skewing.  
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Figure 27: Reduced bacterial load dampens systemic inflammation in Rag2R229Qmice. 
A) Representative FACS dot plots and frequencies of Th1, Th17 and Th1/Th1,7 (B) 
CCR9+-expressing T cells and GITR+ Treg cells (C) from spleen of ABX-treated 
Rag2R229Q mice and controls. (D) Serum level of IFNγ and TNFα. (E) Representative 
kidney, liver and lung-sections from ABX-treated Rag2R229Q mice, Rag2R229Q mice and 
Rag2+/+ mice stained with H&E and CD3 immunostaining. Histograms represent the 
number of CD3 positive cells per area. Asterisks indicate the area of infiltration. (F) 
Transcriptional level of several chemokines from intestinal tissues. (G) Serum level of 
immunoglobulins. 8-12 week-old mice of indicated genotypes were analysed. Mann 
Whitney test; values are mean ± SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
99 
	
 
Figure 28: Faecal transplantation in Rag2R229Q mice. (A) Frequency of Th17, Th1 and 
Th1/Th17 cells in the small intestine, colon and spleen of Rag2R229Q mice and Rag2+/+ 
mice after faecal transplantation treatment. 8-12 week-old mice of indicated genotypes 
were analysed. Mann Whitney test; values are mean ± SEM. *, P < 0.05; **, P < 0.01; 
***, P < 0.001. 
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9.2 Study of the skin pathology in Rag2R229Q mice 
9.2.1 Rag2R229Q mice exhibit severe skin inflammation 
Rag2R229Q mice developed a severe inflammatory skin disease characterized by marked 
infiltration of oligoclonal-activated T cells [47, 65]. Approximately 10% of Rag2R229Q 
mice developed erythroderma-like phenotype by 6 months of age, while <1% developed 
other skin manifestations, including psoriasis, vitiligo and alopecia areata (Figure 29A). 
Histologically, the cutaneous inflammation is characterized by increased thickness of 
the epidermis, caused by hyperkeratosis and marked infiltration of immune cells in the 
dermis (Figure 29B). Occasionally, we observed the presence of inflammatory 
formations localized under the dermis and composed mainly by innate cells and few T 
cells. Interestingly, increased cellularity was detected in the skin of Rag2R229Q mice 
compared to Rag2+/+ mice (Figure 29C). Immunophenotypic analysis of the skin 
infiltrate by flow cytometry confirmed an expansion of CD45+ cells, particularly of 
CD4+ and CD8+ T cells (Figure 29D-E). In agreement, the expression of the chemokine 
receptor cxcr3, normally present on activated T cells, was augmented in mutant skin 
(Figure 29F). Interestingly, the epidermal alterations and the dermal lymphocytic 
infiltration were much more pronounced in mutant mice developing erythroderma-like 
phenotype (Figure 29G). Remarkably, the γδ T cell population was completely absent 
in the skin compartment of mutant mice, reflecting also its impaired thymic 
development (Figure 29H and data not shown).  
The proportion of cutaneous IFNγ-producing T cells was significantly higher in 
Rag2R229Q mice compared to Rag2+/+ mice. On the contrary, the frequency of Th17 did 
not change significantly, in agreement with the defect in γδ T cells, main producer of 
IL-17 in the skin (Figure 29I). Collectively, these results suggest that in Rag2R229Q mice 
skin inflammation is associated to the prominent accumulation of IFNγ-producing 
conventional T cells in the absence of γδ T cells.  
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Figure 29: Characterization of cutaneous inflammation in Rag2R229Q mice. A) 
Cutaneous phenotype in OS disease: from the right, Rag2R229Q mice affected by 
erythoderma, vitiligo and alopecia areata. B) Representative skin section of Rag2R229Q 
mice with erythroderma-like phenotype stained with H&E (right) and CD3 
immunostaining (left). Higher magnification revealed a marked inflammatory CD3+ 
infiltrate in the mutant dermis. Asterisk indicates the area of infiltration. C) 
Representative skin sections from Rag2+/+ and Rag2R229Q mice (8-12 weeks old) at 
steady state, stained with H&E and CD3 immunostaining. Histogram shows 
inflammation score in the skin. D) Representative FACS plots showing TCRγδ T cells 
within CD45+ population from skin tissue of Rag2+/+ and Rag2R229Q mice. (E) Total 
cellularity from skin of Rag2R229Q mice and controls. (F) Cumulative frequencies of 
CD45+ cells, (G) CD4+ T cells and CD8+ T cells. (H) Transcriptional expression of 
cxcr3 on skin tissue. (I) Representative FACS plots and cumulative frequencies of 
cutaneous IL-17- and IFNγ- producing CD3+ T cells. 8-12 week-old mice of indicated 
genotypes were analysed. Mann Whitney test; values are mean ± SEM. *, P < 0.05; **, 
P < 0.01; ***, P < 0.001.  
9.2.2 Coexistence of skin and gut homing properties distinguishes the CD4+ T cells in 
Rag2R229Q mice   
Chemokine receptor CCR4 and its ligands, CCL17 and CCL22, are crucial for the 
recruitment of memory T cells into the skin in several cutaneous immune conditions 
[182]. In agreement with the consistent lymphocytic infiltration, the frequency of 
CCR4-expressing CD4+ T cells in the DLNs, spleen and MLNs of Rag2R229Q mice was 
higher compared to wild-type mice (Figure 30A). This correlated with increased levels 
of serum CCL17 and CCL22 (Figure 30B). Remarkably, we observed that a significant 
proportion of these CCR4+ CD4+ T  cells in mutant mice expressed also the gut-homing 
receptor CCR9, indicative of dual pattern of T cell migration. As expected, the 
expression of CCR9 on CD4+ T cells was higher in Rag2R229Q mice compared to 
controls. Moreover, the proportion of CCR9- CCR4- expressing CD4+ T cells was 
reduced in the lymphoid organs of mutants (Figure 30A).       
We also checked the CCR4+ and CCR9+ co-expression on CD8+ T cells, but we did not 
detect any significant changes (data not shown). This datum suggests that memory T 
cells in Rag2R229Q mice can recirculate between skin and intestinal mucosa. 
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Figure 30: Increased skin and gut homing receptors in Rag2R229Q mice. A) 
Representative dot plots and frequency of the CCR4+, CCR4+CCR9+, CCR9+ and 
CCR4-CCR9- expressing CD4+ T cells from MLN, spleen and DLN of Rag2R229Q mice 
and controls. B) Mouse serum level of CCL17 and CCL22. 8-12 week-old mice of 
indicated genotypes were analysed. Mann Whitney test; values are mean ± SEM. *, P < 
0.05; **, P < 0.01; ***, P < 0.001.  
9.2.3 RAG patients showed increased frequency of CLA-expressing effector T cells      
We had the opportunity to test the levels of CCR4-ligands in the sera of four OS 
patients bearing mutations in RAGs genes. Consistently with mouse findings, we 
detected increased serum level of CCL17 and CCL22 in RAG patients, compared to 
paediatric age-matched healthy donors (HD) (Figure 31A). In humans, cutaneous 
lymphocyte-associated antigen (CLA) expression targets skin-associated T cells to 
inflammatory cutaneous sites [183]. We checked also the expression of gut and skin 
homing receptors on CD4+ CD45RO+ or CD8+ CD45RO+ T cell subsets from PBMCs 
of RAG patients and HDs. Interestingly, we found increased expression of CLA on 
CD4+ CD45RO+ T cells and on CD8+ CD45RO+ T cells in RAG patients compared to 
controls, reflecting their preferential skin-migratory capacity. On the contrary, RAG 
patients showed lower frequencies of CCR9-expressing effector T cells. Moreover, we 
did not observe significant changes in the frequencies of CD4+ CD45RO+ and CD8+ 
CD45RO+ T cells expressing both gut and skin homing receptors (Figure 31B-C).  
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Figure 31: CLA-expressing effector T cells were increased in RAG patients. A) 
Human serum levels of CCL17 and CCL22. B) Representative dot plots and frequencies 
of CLA and CCR9 on CD45RO+ of CD4+ or CD8+ T cells. Mann Whitney test; values 
are mean ± SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001.  
 
9.2.3 Increased cutaneous DC trafficking characterized the Rag2R229Q mice 
Skin-derived DCs imprint skin homing tropism on T cells upon activation [184]. To 
investigate the role of DCs in the homing properties acquired by mutant T cells, we first 
assess the antigen-presentation capacity of cutaneous DCs from the Rag2R229Q mice. 
Mouse ears contain lymphatic vessels that drain to the cervical LNs [185]. DCs are 
physically positioned to take up antigens from the skin and to carry them to the lymph 
nodes via lymphatic system. For tracking DC migration from the skin, APC-labelled 
OVA antigen was intra-dermally injected in the ears of mutant and control mice and its 
uptake by DCs was evaluated in the skin and cervical LN after 6h (Figure 32A). 
Interestingly, while similar frequencies of OVA-loaded DCs were detected in the 
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Rag2R229Q and Rag2+/+ skin tissue (Figure 32B), an higher proportion of DCs carrying 
the OVA antigen was recovered in the cervical LNs of mutant mice compared to 
controls (Figure 32C), indicating an augmented trafficking from the skin. The homing 
programming of T cells by skin-derived DCs may also occur in lymphoid organs, other 
than cutaneous DLNs [186]. In Rag2R229Q mice, lymph nodes are atrophic and devoid of 
germinal centres. Since the immature structures of the mutant LN would not allow the 
immune cell resting, we investigated whether mutant DCs could be able to traffic and to 
present antigens to T cells also in the periphery. To test this hypothesis, Rag2+/+ and 
Rag2R229Q mice were immunized on ear skin with OVA plus CT as adjuvant. After 4 
days, CD11C+ cells were isolated from cervical LN and spleen and co-cultured with 
OT-II cells. At day 6 of culture, OVA-triggered T cell proliferation was evaluated by 
Thymidine incorporation (Figure 32D). We found that DCs isolated from cervical LNs 
of Rag2R229Q mice induced less proliferation in OT-II cells compared to wild-type DCs 
(Figure 32E). In contrast, DCs recovered from the spleen of mutant mice were more 
potent stimulators of OT-II cell proliferation than control cells (Figure 32F). Since WT 
and mutant DCs were able to activate T cells to similar extent when exogenous OVA 
was added directly to the culture (data not shown), these results indicate that the DC 
populations isolated from these anatomical locations were differentially enriched in 
OVA-loaded cells between Rag2R229Q and wild-type mice. Furthermore, these findings 
would suggest that whereas in wild-type mice skin immunization generates 
preferentially local (within the skin DLNs) DC-T cells interaction, in mutant mice skin-
derived DCs are able to traffic and activate T cells in the periphery. 
 
 
 
 
 
 
 
 
107 
	
 
 
Figure 32: Increased DC trafficking in Rag2R229Q mice. A) APC-labelled OVA was 
injected intra-dermally into ears of Rag2R229Q mice and controls. After 6h, OVA-loaded 
DCs were analysed in the skin and in the cervical LN by FACS. B) Representative dot 
plot and frequency of OVA-loaded CD11C+MHCII+ cells in the skin. C) Representative 
dot plot and frequency of OVA-loaded CD11C+ cells in the cervical LNs. D) Rag2R229Q 
mice and controls were immunized with CT + OVA on ear skin.  After 4 days, DCs were 
isolated from cervical LN and spleen. DC and OT-II cells were plated for co-culture 
(1:1 DC:T cell ratio). After 6 days, the proliferation of OT-II cells was assessed by H3-
thymidine incorporation after culture with DCs sorted from DLNs (E) and spleen (F). 
The average of triplicates is shown. 8-12 week-old mice of indicated genotypes were 
analysed. Mann Whitney test and unpaired t test; values are mean ± SEM. *, P < 0.05; 
**, P < 0.01; ***, P < 0.001.  
9.2.4 Increased vascularity characterizes the skin of Rag2R229Q mice  
The cutaneous lymphatic system plays a major role in controlling the local immune 
response [187]. To investigate whether chronic skin inflammation in OS might also be 
associated with increased vascular permeability, we injected Evans blue dye intra-
dermally into the back of Rag2R229Q mice (Figure 33A). Evans blue is specifically taken 
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up by the lymphatic vasculature upon intradermal injection [188]. After 16h, the dye 
was extracted from the mouse back and quantified by ELISA. This analysis showed that 
the Rag2R229Q mice had significantly less amount of Evans Blue remaining localized in 
the skin compared to WT mice, indicative of enhanced lymphatic clearance (Figure 
33B). Consistently, increased cutaneous expression of the vascular endothelial growth 
factor (VEGF-)A, representing the major driver of vascular remodelling and hyper-
permeability, was detected in mutant mice (Figure 33C). Thus, increased lymphatic 
network and augmented lymphatic drainage characterized the skin environment of 
Rag2R229Q mice.    
 
 
Figure 33: Increased lymphatic network in Rag2R229Q mice. A) Evans Blue dye was 
intra-dermally injected into the back of Rag2R229Q mice and controls and was extracted 
after 16h. The total amount of dye remaining in the skin tissue was normalized on gr of 
tissue. B) Blue Evans dye remained in the skin tissue after 16h. C) Transcriptional level 
of VEGF-A in skin tissue. RNA contents are shown as arbitrary units (A.U.). 8-12 week-
old mice of indicated genotypes were analysed. Mann Whitney test and unpaired t test; 
values are mean ± SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001.  
   
9.2.5 Epidermal barrier dysfunction characterizes the cutaneous compartment of 
Rag2R229Q mice 
The epidermal layer has a key role in the maintenance of the skin homeostasis, and 
alterations in its integrity could lead to the penetration of environmental antigens and 
induce immune reactions, contributing to chronic inflammation [189]. At steady state, 
the epidermis of Rag2R229Q mice appears thickened compared to WT mice (Figure 
34A). Consistently, the expression of keratin 5 (CK5) and keratin 6 (CK6) was 
significantly augmented in the mutant skin, underlying the increased production by 
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epidermal keratinocytes (Figure 34B). In agreement, we found higher expression of 
Loricrin, which facilitate the terminal differentiation of the epidermis (data not shown). 
Tight junction (TJ) abnormalities have been described in several skin inflammatory 
diseases, including atopic dermatitis [190]. However, the transcriptional analysis of the 
TJ-related protein (Claudin-4, ZO1 and Occludin) expression did not show significant 
alteration (data not shown). Acute and chronic injury leads to the induction of Cathelin-
related antimicrobial peptides, Cramp and β-defensin 3 (mBD3), which are essential for 
the maintenance of barrier integrity [191]. Interestingly, we detected at least 0.5-fold 
increase of these peptides in the mutant skin, indicative of enhanced microbial 
stimulation of the cutaneous epithelium (Figure 34C). Consistently, bacteria adherent 
to the skin epithelium, measured as a ratio between prokaryotic to eukaryotic DNA, 
were significantly augmented in the mutant mice (Figure 34D). TLRs expression by 
keratinocytes are crucial for sensing skin invading pathogens and promoting cutaneous 
immune responses [192]. Expression of several TLRs, including TLR2, TLR3, TLR4, 
TLR5, TLR9 as well as the adaptor molecules Myd88 and TRIF, was markedly 
increased in the skin tissue of mutants (Figure 34E and data not shown). Together these 
findings indicate that Rag2R229Q mice are characterized by altered barrier integrity and 
increased cutaneous bacterial load.  
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	Figure 34: Alteration of the skin barrier integrity in Rag2R229Q mice. A) 
Representative skin sections from Rag2+/+ and Rag2R229Q mice stained with H&E. B) 
Gene expression analysis of CK5 and CK6 in the skin tissue of mice. RNA contents are 
shown as arbitrary units (A.U.). C) Tissue mRNA expression of antimicrobial peptides. 
Results are shown as fold increase compared to wild-type mice. D) Quantitative PCR 
analysis of cutaneous adherent bacteria in Rag2+/+ and Rag2R229Q mice expressed as 
prokaryotic/eukaryotic DNA ratio. E) Gene expression analysis of TLRs in the skin 
tissue. RNA contents are shown as arbitrary units (A.U.). 8-12 week-old mice of 
indicated genotypes were analysed. Mann Whitney test; values are mean ± SEM. *, P < 
0.05; **, P < 0.01; ***, P < 0.001. 
 
9.2.6 Selective shift in Rag2R229Q skin microbiota 
Based on these results, we next analyzed the resident skin microbiota in Rag2R229Q mice 
and their co-housed WT littermates by 16s rRNA gene profiling. Although we did not 
find significant differences in microbiota intra-sample (α) diversity, as determined by 
Shannon and Chao1 indexes (data not shown), we applied the LEfSe analysis to identify 
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bacterial taxa that were differentially abundant between the two groups.  The analysis 
revealed that the relative abundance of two out of the four dominant taxa populating the 
skin organ, Actinobacteria and Firmicutes, were diminished in Rag2R229Q mice 
compared to controls (p-value <0.05). Moreover, at the genus level of classification, 
Propionibacterium (p-value <0.05) (division Actinobacteria), Streptococcus and 
Staphylococcus (p-value <0.05) (division Firmicutes) were less represented in the 
Rag2R229Q skin microbial composition, suggesting an important shift towards the loss of 
skin commensals (Figure 35). Indeed, the reduction of several cutaneous bacteria could 
impact severely on the skin ecology. For instance, Staphylococcus epidermis has 
beneficial functions, producing a variety of antimicrobial molecules, such as phenol 
soluble modulins, that interact with and cause leakage of lipid microbial membranes 
[193]. Furthermore, Propionibacterium acnes ferments carbohydrate to propionic acid, 
a SCFA with antimicrobial activity [194]. Overall these results underlined a selective 
shift in the microbial composition of skin microbiota of Rag2R229Q mice, thus possibly 
contributing to its pathological state. 
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Figure 35: Skin microbiota differs between Rag2R229Q mice and controls. A linear 
discriminant analysis effect size (Lefse) identifies the significant different abundance of 
bacteria taxa between Rag2R229Q mice and controls. The taxa with significantly different 
abundances among the genotypes are represented by colored dots. From the center 
outward, they indicate the kingdom, phylum, class, order, family, and genus levels. The 
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colored shadows represent trends of the significantly differed taxa. 8 week-old mice of 
indicated genotypes were analysed. Mann Whitney test; P < 0.05 was considered 
statistically significant.   
9.2.7 Chronic activation of epithelial cells sustains skin inflammation in Rag2R229Q mice 
Constant microbial stimulation might induce keratinocytes activation. Activated 
keratinocytes produce inflammatory cytokines, adhesion, activatory and costimulatory 
molecules, which may allow them to act as primary antigen presenting cells (APC) 
[195]. In Rag2R229Q mice, a significant fraction of epithelial cells expressed the MHCII 
molecules at high levels compared to controls, indicative of their activated status 
(Figure 36A-B). The frequency of proliferating Ki67+ epithelial cells did not differ 
significantly between mutants and controls (data not shown). However, a high number 
of proliferating Ki67+ cells resides in the epidermis and in the dermis of Rag2R229Q mice 
with erythroderma-like phenotype (data not shown). To completely characterize the 
cutaneous inflammatory environment in the Rag2R229Q mice, we measured the 
expression levels of several cytokines. Transcript mRNA of IFNγ, IL-13, TNFα, IL-23, 
IL-1β, IL-5, IL-33 and TSLP were significantly up-regulated in the Rag2R229Q skin, 
whereas, as expected, the IL-17 expression did not change significantly (Figure 36C). 
Moreover, keratinocytes play an important role in orchestrating immune responses by 
producing chemokines following TLR engagement [196]. Consistently, transcript levels 
of cxcl9, cxcl10, ccl20, ccl22 and ccl17 chemokines were significantly up-regulated in 
the skin of Rag2R229Q mice (Figure 36D). To test whether this inflammatory 
environment has a role in determining cutaneous T cell migration in Rag2R229Q mice, we 
employed the trackable OVA-TCR transgenic system and adoptively transferred CD4 or 
CD8 splenocytes from OT-II or OT-I mice into Rag2+/+ and Rag2R229Q recipients. Then, 
we topically immunized the ears once with OVA plus CT [144]. After 7 days, treated 
chimeric mice were sacrificed and cells were isolated from cervical LNs and skin 
biopsies (Figure 37A). Interestingly, OT-II cells were dramatically enriched within the 
skin and cervical LNs of OVA-treated Rag2R229Q mice compared to controls (Figure 
37B-C). The same enrichment was evident for OT-I cells (Figure 37D-E). This 
accumulation was Ag-dependent, because CT alone did not induce a relevant 
accumulation of OT-I or OT-II cells (Figure 37B-D). Overall, these findings indicate 
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that epithelial cells have the potential to release several chemokines that direct T cell 
infiltration at the cutaneous site.  
 
 
		
	
Figure 36: Activated epithelial cells in Rag2R229Q mice. A) Representative FACS plots 
and frequency of CD45-MHCII+ and CD45-MHCII+ cells in the skin of Rag2R229Q mice 
and controls. B) Mean fluorescent intensity (MFI) of MHCII on CD45- cells.  
Transcriptional level of cytokines (C) and chemokines (D) in the skin tissue. 8-12 week-
old mice of indicated genotypes were analysed. Mann Whitney test; values are mean ± 
SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001;**** P < 0.0001. 
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Figure 37: Enrichment of OVA-specific OT-II or OT-I cells in the Rag2R229Q skin. A) 
Splenic OT-II CD4+ T cells or OT-I CD8+ T cells were injected i.v. into mismatched 
host mice. Rag2R229Q mice and controls were immunized in the ears with OVA plus CT 
or only CT. The enrichment of OT-II cells or OT-I cells in OVA-inflamed skins and 
cervical LNs were assessed at day 7. Representative dot plots of OT-II (B) or OT-I cells 
(D) from CT-treated mice and CT+OVA-treated mice from DLNs. Representative dot 
plots and frequency of OT-II cells or OT-I cells (C, E) within the skin at day 7. 8-12 
week-old mice of indicated genotypes were analysed. Mann Whitney test; values are 
mean ± SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001.   
 
9.2.8 LPS-induced inflammation is profoundly enhanced in Rag2R229Q mice 
Since we found that Tlr4 was the most highly expressed Toll-like receptor in the mutant 
skin, we tested the effect of acute stimulation by LPS-intradermal injection. In 
particular, mice received a single intradermal injection of 100 µg LPS on the right and 
PBS on the left. Mice were then sacrificed 24h later. (Figure 38A). Haemorrhage and 
dermal tissue necrosis was evident at the injection site 24h after LPS injection in all 
treated mice. Histological examination of cutaneous tissue revealed widespread 
epidermal thickening, increased abscesses formation and profound haemorrhage in 
Rag2R229Q mice. However, mild signs of haemorrhage were evident also in Rag2+/+ 
mice (Figure 38B). To further explore the effect of LPS on skin tissue, we analysed the 
expression of pro-inflammatory cytokines, IFNγ and IL-1β. Both cytokines resulted 
strikingly elevated in mutant mice treated with intradermal LPS compared to controls. 
Moreover, the increased expression of the chemokine Cxcl2 has the potential to induce 
a robust recruitment of innate cells to the mutant skin (Figure 38C), indicating that Tlr4 
stimulation induced strong inflammatory response in mutant mice. 
As a consequence of the altered intestinal permeability, we have demonstrated high 
level of LPS in the circulation of Rag2R229Q mice [197]. Therefore, to directly test 
whether endogenous level of serum LPS could be involved in the chronic stimulation of 
skin epithelium in Rag2R229Q mice, we examined the cutaneous responses to systemic 
LPS. Mice received a single injection of 100 µg LPS i.p and were sacrificed 24h later 
(Figure 39A). Rag2R229Q mice displayed a strong cutaneous inflammatory response to 
systemic LPS, characterized by dramatic upregulation of skin Tlr4 mRNA and 
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expression of IFNγ (Figure 39C). Histologically, Rag2R229Q mice showed a worsened 
inflammatory picture characterized by epidermal thickness with hyperkeratosis, 
occasionally abscesses and marked dermal inflammatory infiltrate. Signs of cutaneous 
inflammation were evident also in the skin of Rag2+/+ LPS-treated mice, which reached 
the score of untreated Rag2R229Q mice (Figure 39B). These data let us to hypothesize 
that peripherally translocated intestinal derived-LPS or other microbial products could 
be involved in the chronic stimulation of skin epithelium and activation of cutaneous 
immunity.   
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Figure 38: Intradermal LPS induces profound inflammation in Rag2R229Q mice. A) 
Dorsal skin of Rag2R229Q mice and controls were injected s.c. with LPS (right side) or 
PBS control (left side). B) Representative skin sections from LPS-treated Rag2+/+ and 
Rag2R229Q mice and controls stained with H&E. C) Transcriptional analysis of cytokines 
in the total skin tissue. 8-12 week-old mice of indicated genotypes were analysed. Mann 
Whitney test; values are mean ± SEM. *, P < 0.05; **, P < 0.01. 
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Figure 39: Systemic LPS induces strong inflammatory reaction in the skin of 
Rag2R229Q mice. A) Rag2+/+ and Rag2R229Q mice were treated with LPS systemically. B) 
Inflammatory score and representative skin sections from systemic LPS- treated 
Rag2+/+ and Rag2R229Q mice and controls. C) Cutaneous tissue expression of cytokines. 
8-12 week-old mice of indicated genotypes were analysed. Mann Whitney test; values 
are mean ± SEM. *, P < 0.05; **, P < 0.01. 
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9.2.9 Chronic DSS treatment increases T-cell mediated skin inflammation in Rag2R229Q 
mice 
To better investigate the link between intestinal inflammation, altered gut barrier 
permeability and skin degenerations in Rag2R229Q mice, we sought to directly probe the 
role of gut inflammation in the homing of T cells to the cutaneous site. Therefore, we 
boosted intestinal inflammation in Rag2R229Q mice by treating them with DSS. 
Histological analysis performed 4 weeks after the beginning of the chronic treatment 
revealed marked signs of skin inflammation in Rag2R229Q mice, including epidermal 
thickness, hyperkeratosis and dermal CD3+ T cell infiltration (Figure 40A). 
In contrast, such skin alterations were not observed in DSS-treated Rag2+/+ mice. 
Inflamed skin undergoes vascular remodelling, consisting of enlarged network of 
vessels with increased blood flow and influx of inflammatory cells [198]. To test 
whether vascular changes affect the skin compartment of DSS-treated-Rag2R229Q mice, 
we analysed the blood vascular system by immunostaining for CD31. At steady state, 
we detected increased vessels coverage (% on area dermis) and number of blood vessels 
in Rag2R229Q mice compared to controls, indicative of the vascular alteration. However, 
mutant blood vessels did not show changes in size measured by morphometric analysis. 
Interestingly, DSS-triggered inflammation led to blood vessel enlargement in the mutant 
skin (Figure 40B-D), which might potentially favour the influx of immune cells to the 
skin.  
In parallel, we detected higher expression of T cell and innate cell-recruitment 
chemokines (Figure 40E). Consistently, we observed that the expression of MHCII 
marker was augmented in the CD45neg fraction of the skin cell suspension of Rag2R229Q 
mice, indicative of epithelial cell hyper-activation upon DSS treatment. Moreover, 
analysis by FACS of cutaneous cell suspension confirmed that the proportion of CD4+ T 
cells and CD8+ T cells within the skin of DSS-treated Rag2R229Q mice was augmented of 
2-4 fold (Figure 40F). Overall, these findings suggest that chronic intestinal 
inflammation, typical of OS, induces extensive vascular skin alterations, resulting in 
marked influx of immune cells to the cutaneous site. In parallel, the intestinal barrier 
breakdown induced by DSS results in the release of LPS or other microbial peptides 
that may stimulate epithelial cells to release chemokines, contributing to the T cell 
migration to the cutaneous site.  
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Figure 40: Intestinal inflammation affected skin compartment in Rag2R229Q mice. A) 
Representative skin section from Rag2+/+, Rag2R229Q, and DSS-treated Rag2R229Q mice, 
stained with H&E and CD3 immunostaining. Histogram shows the inflammation score. 
Asterisks indicate the area of infiltration. Semi-quantitative analysis of vessels coverage 
(% on area dermis) (B), number of vessels (on area dermis) (C) and average size 
vessels (µm) of controls and DSS-treated Rag2R229Q mice (D). (E) mRNA expression of 
several cytokines on skin tissue. (F)MFI of MHCII on CD45- of Rag2R229Q mice and 
DSS-treated Rag2R229Q mice. Fold increase of CD4+ and CD8+ T cell population in the 
skin of DSS-treated Rag2R229Q mice compared to controls. 8-12 week-old mice of 
indicated genotypes were analysed. Mann Whitney test; values are mean ± SEM. *, P < 
0.05; **, P < 0.01; ***, P < 0.001.   
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10. DISCUSSION 
 
10.1 Study of the intestinal pathology in Rag2R229Q mice  
Hypomorphic mutations in the RAG genes lead to a profound immunodeficiency 
associated to multisystem autoimmune like-manifestations, mediated by oligoclonal 
self-reactive T cells [19, 65]. The severity of the clinical phenotype of RAG deficiency, 
correlates, at least in part, with the residual level of recombination activity of the mutant 
protein. However, environmental factors are also important, because patients with 
similar severe mutations may present with distinct phenotypes. In this regard, OS 
patients are highly susceptible to infection and develop fungal, bacterial and viral 
infection typical of SCID. Moreover, diet and lifestyle factors could also influence the 
disease. Furthermore, alteration of the intestinal microbiota has been recently associated 
with several inflammatory diseases, including IBD, rheumatoid arthritis and multiple 
sclerosis, but not yet explored in PIDs. Here, we demonstrated the crucial role of 
intestinal microbiota in driving the OS pathogenesis. 
A primary goal of this thesis was to investigate the role of the intestinal immune 
responses and gut microbiota in the OS pathogenesis. We found that hypomorphic 
Rag2R229Q mice manifest inflammatory-bowel illness, affecting both large and small 
intestine, characterized by marked T cell infiltration involving, intriguingly, also T 
regulatory cells. A broad variability in the inflammatory parameters emerged by the 
histopathological analysis of the mutant intestine, despite the presence of the same 
mutation. Similarly to humans, the stochastic nature of V(D)J rearrangements 
generating the T cell repertoire in combination with environmental factors may impinge 
on the inflammatory state in mice.   
Moreover, a dominant mixed Th1/Th17 cell skewing, implicated in the experimental 
colitis in mice as well as in the pathogenesis of IBD, characterized the intestinal 
compartment of Rag2R229Q mice [199, 200]. Consistently, we showed that mutant CD4+ 
T cells, either isolated from apparently healthy or colitic mice, are sufficient to transfer 
the disease into immune-deficient hosts. However, recent data demonstrated that 
together with CD4+ T cells, CD8+ T cells participate to immune responses in IBD [201]. 
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Thus, we could not exclude that CD8+ T cells have also been implicated in driving 
intestinal inflammation.  
 
In the gastrointestinal tract, T regulatory cells play a pivotal role in maintaining immune 
homeostasis and promoting tolerance against intestinal antigens and commensal bacteria 
[202]. In this thesis, several experiments addressed the role of Tregs in OS 
pathogenesis. In particular, Rag2R229Q Tregs accumulate in the intestinal mucosa but fail 
to control intestinal inflammation, suggesting that mutant Tregs may not be functionally 
competent. By using an adoptive transfer model of colitis, we have demonstrated that 
Rag2R229Q Treg cells co-transferred with wild-type CD45RBhi CD4+ T cells are unable 
to control intestinal disease progression in an immunodeficient host. Moreover, the 
transfer of a limited number of wild-type Tregs ameliorates the intestinal inflammation 
in Rag2R229Q mice, and is associated to the reduction of Th1/Th17 mucosal immune 
responses. Importantly, it has been shown that high TCR diversity is required for Tregs 
to maintain the tolerance to intestinal microbiota [176]. In this context, Rag2R229Q mice 
might display selective defects in the acquisition of tolerance to commensal microbial 
stimuli because of the Treg oligoclonality, potentially skewing intestinal homeostasis to 
Th1/Th17 inflammation. Our findings suggested that Treg cells are not functionally 
competent, thus contributing to the autoimmunity of the OS disease.  
 
Mucosal Tregs, together with secretory IgAs, critically protect the gut barrier integrity 
and control the microbiota diversification, thus maintaining the host-bacterial 
mutualism [104]. On the other hand, several bacterial species compromise intestinal 
barrier and induce immune hyperactivation, leading to the development of pro-
inflammatory T cell responses [105, 203]. Here, we have shown that Rag2R229Q mice are 
affected by a general B cell deficiency at the mucosal interfaces. Consistently, the 
analysis of the intestinal microbiota in Rag2R229Q mice revealed a reduced bacterial 
diversity and enrichment of many genera belonging to Proteobacteria phylum, recently 
associated to IBD development in patients [204]. Additionally, we found high levels of 
serum LPS in Rag2R229Q mice, indicating an important defect in the permeability of gut-
blood barrier. Together these findings indicated that mucosal B cell deficiency in 
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Rag2R229Q mice favours microbial access to the LP and circulation and impacts 
considerably on the microbial biodiversity.  
 
Collectively, due to the relevance of RAG genes in the generation and the function of 
adaptive immune system impairment, different types of T and B cells are affected 
causing systemic disease. Our findings demonstrate that Treg functionality and B cell 
deficiency could both participate to the development and progression of intestinal 
disease in multiple synergistic ways. Importantly, the analysis of B and T cell 
compartment in adoptive cell transfer experiments could help to address how different 
populations interact among each other contributing to OS pathogenesis.     
 
The clinical benefits deriving from antibiotic treatment implicate commensal bacteria in 
the pathogenesis. Long-term antibiotic treatment significantly improved the intestinal 
inflammation in Rag2R229Q mice. In particular, we demonstrated that both mucosal and 
systemic pro-inflammatory Th1 and Th17 cells were significantly decreased in ABX-
treated mice, indicating that Th- skewing in Rag2R229Q mice is microbiota-dependent. 
Consistently, we showed that the transfer of altered microbiota isolated from Rag2R229Q 
mice was sufficient to induce a skewed Th1/Th17 pro-inflammatory phenotype in 
Rag2+/+mice, suggesting the pathogenic pro-inflammatory properties of the mutant 
microbiota, independently of the genetic susceptibility. Additional co-housing 
experiments would help to shed light more on the role of the microbiota in the 
pathogenesis. Furthermore, we observed that the majority of circulating CCR9+ T cells 
markedly reduced after ABX treatment. Since CCR9 marker is commonly expressed by 
T cells upon priming by GALT-dendritic cells [205], we speculate that its presence on 
the majority of T cells may reflect their intestinal origin.  
 
The signalling via MyD88 plays an important role in intestinal homeostasis. In contrast 
to previous studies describing its protective effects on IBD induced by immune 
deficiencies [206, 207], we observed that inhibition of Myd88 did not protect Rag2R229Q 
mice from intestinal inflammation. Moreover, several works demonstrated that Myd88-
dependent pathway is required for the induction of both Th1 and Th17 immune 
responses [208, 209]. Our data clearly demonstrated that signalling through Myd88 is 
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crucial only for Th1 differentiation, but not essential for the Th17 generation and other 
sensors might be involved in the Th17 generation. As instance, Atarashi and 
collaborators proposed a Myd88/TRIF independent and ATP dependent mechanism of 
Th17 development in the intestine [95].  
  
Many studies underlined the ability of intestinal microbiota to extend their effects 
beyond the gastrointestinal tract via immune system modulation. Importantly, reducing 
intestinal microbial load visibly reduced the systemic autoimmunity in Rag2R229Q mice. 
In particular, a decreased number of infiltrating T cells was detected in the kidney, liver 
and lung after ABX treatment in Rag2R229Q mice. In contrast, skin inflammation did not 
apparently benefit from ABX treatment. Different explanations could be considered: 1) 
to be effective at the cutaneous compartment, which likely experiences diverse drug 
absorption kinetics compared to systemic organs, the oral treatment with ABX might 
require different dosage and/or administration time; 2) the resident skin microbiota 
might have a synergistic, yet prominent, role in controlling and modulating local T cell 
responses in Rag2R229Q mice.  
Moreover, our findings revealed that reducing bacterial load with antibiotics was 
beneficial for normalizing serum IgE levels, the clinical hallmark of the disease. Our 
previous findings indicate that B cell abnormalities and plasma cells differentiation are 
dependent on the presence of hyperactivated CD4+ T cells [44]. In ABX-treated 
Rag2R229Q mice, the dramatic drop in IgG1, IgA and particularly in IgE production, 
compared to controls, could be related to the reduced serum concentration of cytokines, 
responsible for promoting class switch recombination. Microbial exposure during early 
life and a critical level of bacterial diversity are crucial to establish a proper 
immunoregulatory network, inhibiting IgE production [210]. In this regard, high IgE 
serum levels in mutant mice may reflect the low bacterial diversity that is likely 
defective in promoting immune regulation.  
 
Based on our findings, microbial-induced proliferation could explain the significant 
number of T cells in the intestinal LP of mutants, in sharp contrast with the overall 
lymphoid depletion found in other peripheral organs.  In addition to this mechanism, we 
could not exclude that a small proportion of T cells is generated in extra-thymic sites, in 
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particular locally in the gut. In athymic mice, it has been shown that during embryonic 
stage, γδ T cells develop within the gut and do not require the thymic education for their 
differentiation [211]. In this regard, gut cryptopatches, small aggregates of lymphocytes 
at close contact of the epithelium are the extrathymic source of lymphopoiesis [212]. 
Future studies will investigate the mutant intestine as potential site for T cell generation.  
 
In summary, hypomorphic Rag defects compromise gut barrier integrity and alter 
bacterial composition, inducing translocation of the systemic bacterial products in the 
periphery, which sustains immune dysregulation/autoimmunity typical of OS. In 
addition, loss of tolerance to commensal bacteria probably leads to Th1/Th17 
inflammation, which sustains dysbiosis in a well-recognized regulatory loop. 
Decreasing bacterial load in Rag2R229Q mice with long-term antibiotic treatment 
ameliorated both local and systemic autoimmunity, by reducing the frequency of 
circulating CCR9-expressing T cells and Th1/Th17 populations. In addition, serum 
hyper-IgE was normalized upon antibiotic treatment. Overall these findings revealed 
that commensal bacteria might have a crucial role in OS pathogenesis. 
The evidence that this inflammatory immune phenotype is transmissible to an intact 
immune system via microbiota-dependent manner let us to speculate that 
pharmacological gut contamination may constitute a valid strategy to reduce side effects 
of hematopoietic stem cell transplantation in these patients [213]. On the other hand, 
interventions aimed at promoting diversification of the intestinal microbiota may 
improve immunological outcome in OS transplant setting.   
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10.2 Study of the skin pathology in Rag2R229Q mice  
 
This thesis investigated also the role of cutaneous immune responses in the 
pathogenesis of OS. A large portion of mice develops cutaneous abnormalities 
resembling several aspects of human erythroderma. Indeed, although only a minority of 
mutant mice manifests overt skin phenotype at steady state, the majority of them show 
however important cutaneous alterations, including increased epidermal thickness with 
hyperkeratosis and inflammatory infiltrates in the dermis. In particular, we found that 
cutaneous tissue of Rag2R229Q mice exhibited increased cellularity with a prominent 
expansion of CD45+ cells. Importantly, a deeper analysis revealed lack of γδ T cells in 
the skin, confirmed also by its lack in the thymus. Compelling evidence indicates the 
critical role-played by the γδ T cells in tissue homeostasis and repair. In mice lacking γδ 
T cells (TCRδ-/-), wound repair is disrupted and epithelial homeostasis is not 
maintained. Particularly, keratinocytes undergo increased apoptosis and the αβ T cell 
population is not maintained in the epidermis, suggesting the importance of the correct 
TCR for epithelial homeostasis maintenance [214]. Also in the gut compartment, TCRδ-
/- mice showed reduced proliferation of epithelial cells in both large and small intestine. 
Why the γδ T cell development is blocked in the mutant thymus and which 
immunological implications could lead at the mucosal interfaces remains to be 
completely addressed.   
On the other hand, the expanded CD4+/CD8+ T cell populations in the dermis might be 
crucial for driving local inflammation. Indeed, CD8+ T cell are predominantly localized 
to the epidermis, in contrast to the predominantly dermal CD4+ T cells. During infection 
or inflammation, effector CD8+ T cells enter the dermis from the blood and can then be 
recruited into the epidermis [215]. The molecular signals that regulate the abundant 
localization of CD8+ T cells in the dermis of Rag2R229Q mice, instead of the normal 
presence in the epidermis, remain to be identified.     
Moreover, we showed that the resident Rag2R229Q T cells, producing high amounts of 
IFNγ, might constitute the main skin-inflammation drivers. Moreover, the synergic 
activity of other cytokines, including IL-13, TNFα, IL-23, IL-1β, IL-5 and IL-33, 
increase further the inflammatory environment in mutant mice. 
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Recent literature suggests that cutaneous exposure to food antigens can reprogram gut 
homing effector T cells in lymph nodes to express skin homing receptors, eliciting skin 
inflammation [186]. CCR4 constitutes a necessary component of skin specific 
lymphocyte trafficking [144]. In the peripheral lymphoid organs of Rag2R229Q mice, we 
found an increase frequency of CCR4-expressing CD4+ T cells, suggesting enhanced T 
cell migration to the skin compartment, likely due to the cutaneous antigen stimulation. 
Interestingly, a significant proportion of CCR4-expressing CD4+ T cells expressed also 
the gut homing receptor CCR9. This co-expression underlined the dual homing 
potential of T cells to the gut and to the skin. 
This datum opens the possibility that pathogenic gut-originated T cells, once 
disseminated in the periphery, migrate to the skin compartment, by upregulating the 
skin tropic receptor after exposure to skin-derived antigens. 
However, studies in human samples did not reproduce the overall mouse findings: the 
majority of effector T cells express the skin homing receptor CLA in RAG patients 
compared to T cells isolated from the blood of HDs. Importantly, the CCR9+ CLA+ -and 
the CCR9+-expressing T cell populations are almost absent in RAG patients. The reason 
why the expression of CCR9 is lower in RAG patients compared to HDs remains to be 
explained on the basis of clinical findings. Skin rashes and lesions are the hallmark of 
patients with Omenn while IBD-like manifestations occur at low frequency.  This could 
be related to the relative immaturity of intestinal flora in newborns. Indeed, it is known 
that intestinal dysbiosis play a major role in the development of intestinal inflammation. 
Importantly, OS is a severe disease and patients are usually treated with antibiotics and 
immunosuppressive drugs until they undergo HSCT. This represents a great limitation 
for our studies trying to validate mouse findings in humans. Therefore, extend our 
analysis to adult patients affected by chronic intestinal inflammatory diseases associated 
to cutaneous co-morbidities could be useful to investigate our hypothesis.  
 
Dendritic cells have a key role in presenting cutaneous antigens and imprinting T cells 
with skin homing profiles [171]. Interestingly, we have demonstrated that skin-derived 
DC trafficking to draining lymph nodes is increased and strongly correlates with 
abundant lymphatic network in Rag2R229Q mice. Furthermore, we observed that skin-
derived DCs were also able to traffic and activate T cells in the spleen after OVA-
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topical immunization, suggesting that skin barrier defects may eventually increase the 
propensity of antigen-presenting cells to take up antigens and present them to T cells in 
periphery. Thus, overall our results sustain the notion that skin homing reprogramming 
of gut-originated inflammatory T cells is a key pathogenic mechanism contributing to 
skin degeneration in Rag2R229Q mice.  
The recruitment of T cells to the skin is also regulated by several chemokines released 
by keratinocytes [216]. Firstly, we showed that mutant keratinocytes display an 
abnormal activation, which is in agreement with a chronic stimulation sustained by 
environmental and bacterial factors. Moreover, we observed a prominent up-regulation 
in tissue expression of T cell targeting-chemokines that may reflect the marked 
lymphocytic infiltration in the dermis. Consistently, the transfer of OT-1 or OT-II cells 
in Rag2+/+ or Rag2R229Q mice after OVA topical immunization clearly revealed the 
preferential accumulation of T cells into the inflamed skin of Rag2R229Q mice.  
 
The epithelial barriers of our bodies are continually exposed to environmental stimuli 
and must respond properly to maintain the barrier integrity [217]. In our study, we 
found that epidermis thickness was greatly increased in Rag2R229Q mice, correlating 
with the augmented expression of keratin markers. Consistently, we observed increased 
expression of antimicrobial peptides and of several TLRs in the skin tissue of mutant 
mice, indicative of important alterations in the integrity of epithelial skin barrier, which 
may lead to compromised protection against environmental and pathogenic insults. Loss 
of structural and functional barrier integrity, and consequent penetration of pathogens 
induce skin inflammation. Recent studies have correlated the presence of certain 
bacteria with specific disease state. In particular, in psoriatic lesions, Firmicutes are 
more abundant while Actinobacteria and Proteobacteria are relatively less represented 
within the skin commensal community compared to healthy skins [160]. Moreover, 
increased prevalence of Staphylococci, including both S.aureus and S. epidermis, was 
found in patients with atopic dermatitis [218]. Based on these studies, selective shift in 
the skin microbiome has been associated with several skin disorders. Here, have 
demonstrated that Rag2R229Q mice manifested a selective shift in resident skin 
microbiota with decreased abundance of commensal bacteria belonging to 
Actinobacteria and Firmicutes phyla. Specifically, the loss of some bacteria genera 
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(Streptococcus, Staphylococcus and Propionibacterium) might contribute to render the 
Rag2R229Q skin more susceptible to colonization by pathogenic bacteria. Furthermore, in 
mutant mice these alterations were compensated by an important expansion of unknown 
and uncultivable bacteria.  
Interestingly, among the TLRs investigated, we observed that TLR4 was the most 
highly expressed in the mutant skin. Keratinocytes are known to express functional 
TLR4 and secrete pro-inflammatory cytokines in response to TLR4 interaction [219].  
Therefore, we sought to deeper evaluate the effect of TLR4 stimulation on the 
cutaneous compartment of mutant mice. We found that upon LPS intradermal injection, 
the skin of Rag2R229Q mice experienced a strong inflammatory response, characterized 
by important epidermal structural changes and acute Th1 mediated responses. 
Interestingly, such responses were also evident, although to a lesser extent, in the wild-
type mice, in which the inflammatory parameters reached those observed in the mutants 
at steady state, thus supporting the pivotal mechanistic contribution of this microbial 
molecule in the pathogenic mechanisms underlying skin disease in Rag2R229Q mice.  
We reported high levels of LPS in the serum of Rag2R229Q mice, consequence of the 
compromised intestinal barrier permeability [197]. Importantly, we demonstrated that 
this circulating microbial product could have a causative role in determining the chronic 
activation of the cutaneous epithelial barrier in the mutant mice. Sensing of systemic 
LPS by skin epithelial cells is indeed proved by the rapid and significant increase in 
TLR4 tissue expression of mutant mice, following i.p administration. Consistent with 
our conclusions are also reports showing both the presence of, and high reactivity to, 
LPS endotoxins in the blood of patients with skin conditions [220].  
 
Emerging evidence support the existence of communication axes between gut and skin 
organs. It has been documented that atopic dermatitis and rosacea are both associated 
with changes in gut barrier and intestinal microbiota [221, 222]. Furthermore, 
association between imbalances of the intestinal microbiota and development of skin 
inflammation have been described in mice and patients [223, 224]. However, the 
cellular and molecular mechanisms whereby gut inflammation could be linked to skin 
disorders are largely unexplored. In coeliac disease, the generation of circulating 
antibodies, produced by the intestinal immune reaction to gluten, could be able to 
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trigger inflammation and dermatitis [225], confirming the possibility that immune cells 
could traffic in and out the skin compartment. Moreover, cutaneous exposure to food 
antigens was shown to reprogram gut homing effector T cells in lymph nodes to express 
skin homing receptors, eliciting skin inflammation [186]. In OS, systemically 
translocated commensal antigens in the presence of breaches of the gut barrier could 
potentially reprogram T cells to express skin homing potential. Intestinal-derived LPS 
could be considered as a potential trigger in driving this process. However, it remains to 
elucidate whether other microbial compounds could be involved. 
Despite several evidence linking IBD-like disease and skin inflammation in OS 
pathogenesis, the possible mechanisms of gut T cell reprogramming after cutaneous 
antigen exposure remain to be elucidated by future studies. Moreover, the analysis of 
the TCR repertoire of T cells isolated from cutaneous and intestinal sites will be useful 
for supporting our hypothesis.  
 
Multiple disease may arise or be exacerbate due to a leaky gut, including autoimmune 
diaseses, inflammatory bowel disease, celiac disease, autoimmune hepatitis, type 1 
diabetes (T1D), multiple sclerosis, and systemic lupus erythematosus (SLE) [226].                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
In OS mutants, T cells co-express gut and skin homing receptors and showing potential 
trafficking between the mucosal compartments. In particular, we showed that boosted 
intestinal inflammation worsens skin degeneration in Rag2R229Q mice. On the other 
hand, we could not exclude that the skin is the first point of contact where the 
inflammation starts in OS. Indeed, the skin is in direct contact with the environment and 
it is constantly exposed to microorganims. In particular, changes in the resident 
communities could perturb the overall ecosystem to induce disease conditions, even in 
the absence of pathogen colonization. Exposure to allergens or irritants can also trigger 
inflammatory reactions at the cutaneous sites. Testing this other possibility may help to 
shed light on the pathogenic mechanisms underlying OS skin autoimmunity.    
 
Here, we have demonstrated the existence and the contribution of a gut-skin axis in the 
OS pathogenesis. We have first shown that compromised gut barrier integrity and loss 
of tolerance to commensal bacteria leads to systemic Th1/Th17 cell dissemination in 
Rag2R229Q mice [197]. Then, we found that chronic DSS treatment, administered to 
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boost intestinal inflammation in Rag2R229Q mice, worsened the cutaneous disease in 
treated mice, inducing hyper-activation of keratinocytes, abnormal release of leucocyte-
attracting chemokines and enhanced T cell recruitment to the cutaneous site. Thus, these 
results indicate that gut inflammation and dysbiosis significantly impacts on the 
pathogenesis of skin degeneration in Rag2R229Q mice.  
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10.3 Conclusive remarks and future directions 
OS is a peculiar immunodeficiency caused by hypomorphic mutations in RAG genes, 
allowing residual T and B-cell development. OS patients develop IBD-like disease 
associated to a spectrum of cutaneous manifestations, whose underlying immunological 
mechanisms remained incompletely understood. Taking advantage of the mouse model 
of the disease, the Rag2R229Q mice, we have provided novel insights into disease 
pathogenesis, showing that gut commensals and/or commensal bacteria-derived signals 
might play a substantial role in determining the distinctive immune dysregulation and 
autoimmune manifestations in RAG-associated immune deficiency. Moreover, our 
results, indicating that microbiota can constitute a pharmacological target for these 
crucial pathogenetic aspects of the disease, may represent the groundwork for novel 
approaches in OS patient’s management.  
Defects in the function of intestinal mucosal barrier as well as inappropriate immune 
responses to gut microbiota are recognized disease mechanisms of IBD [227]. Based on 
these similarities, understanding of OS disease can complement the comprehension of 
IBD pathogenesis and might also provide novel treatment options for affected patients. 
The skin represents one of the most common extra-intestinal system affected in patients 
with IBD, including CD or UC [228]. The most common cutaneous lesions associated 
with IBD are erythema nodosum, pyoderma gangrenosum, and aphthous stomatitis 
[229]. Other skin manifestations such as psoriasis and vilitigo have been also associated 
[230]. In the gastrointestinal tract, the equilibrium between mucosal epithelium, 
commensal microbes and host immune responses is essential for maintaining intestinal 
homeostasis and mucosal T cells represent the key players [231]. Aberrant T cell 
response to microbial antigens can perturb the equilibrium and could be the mechanism 
that causes inflammation and the release of inflammatory cytokines, resulting in the 
development of IBD [232]. In this context, the extra-intestinal manifestations seen in 
IBD may be the results of immune dysregulation, and, particularly, of a T cell-mediated 
destructive process. For instance, Adams and Eksteen proposed an explanation for IBD 
patients with hepatic complications. In particular, mucosal T cells aberrantly travel from 
the intestine to the liver, becoming exposed to hepatic antigens and, ultimately leading 
to hepatic inflammation [233]. In our study, we have demonstrated that such a 
mechanism could be also at the basis of the communication axes between gut and 
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distant organs, such as the skin, and explain the pathogenesis of a rare form of 
immunodeficiency, presenting with IBD-like intestinal inflammation and skin co-
morbidity. Investigating whether same cellular and molecular dynamics extend to IBD 
patients presenting skin extra-intestinal manifestations could advance the 
comprehension of IBD immunopathology. Furthermore, the management of skin 
manifestations and IBD may benefit from the targeting of the gut-skin axis. It is 
possible that the therapeutic modulation of the intestinal microbiota (via AMPs, 
antibiotics and antiseptics) modifies the secretory, metabolic and hormonal activity of 
the skin, impacting directly on cutaneous inflammation. The ability to modify the 
function of one organ by the manipulation of the other would constitute a novel 
therapeutic strategy.            
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